<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Control</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Control</journal-id><journal-id journal-id-type="hwp">spccx</journal-id><journal-id journal-id-type="publisher-id">CCX</journal-id><journal-title-group><journal-title>Cancer Control : Journal of the Moffitt Cancer Center</journal-title></journal-title-group><issn pub-type="ppub">1073-2748</issn><issn pub-type="epub">1526-2359</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage CA: Los Angeles, CA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40394866</article-id><article-id pub-id-type="pmc">PMC12093012</article-id><article-id pub-id-type="publisher-id">10.1177_10732748251344481</article-id><article-id pub-id-type="doi">10.1177/10732748251344481</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Review of Network Meta-Analyses on the Efficacy of Chemopreventive Agents on Colorectal Adenomas and Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ruan</surname><given-names>Yibing</given-names></name><degrees>PhD</degrees><xref rid="aff1-10732748251344481" ref-type="aff">1</xref><xref rid="aff2-10732748251344481" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0004-6384-3424</contrib-id><name><surname>Carbonell</surname><given-names>Chantelle</given-names></name><degrees>BHSc</degrees><xref rid="aff1-10732748251344481" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Brown</surname><given-names>Karen</given-names></name><degrees>PhD</degrees><xref rid="aff3-10732748251344481" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Hilsden</surname><given-names>Robert J.</given-names></name><degrees>MD, PhD</degrees><xref rid="aff4-10732748251344481" ref-type="aff">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Brenner</surname><given-names>Darren R.</given-names></name><degrees>PhD</degrees><xref rid="aff1-10732748251344481" ref-type="aff">1</xref><xref rid="aff5-10732748251344481" ref-type="aff">5</xref><xref rid="corresp1-10732748251344481" ref-type="corresp"/></contrib><aff id="aff1-10732748251344481"><label>1</label>Department of Oncology, Cumming School of Medicine, <institution-wrap><institution content-type="university">University of Calgary</institution></institution-wrap>, Calgary, AB, Canada</aff><aff id="aff2-10732748251344481"><label>2</label>Department of Cancer Epidemiology and Prevention Research, Cancer Care Alberta, <institution-wrap><institution content-type="university">Alberta Health Services</institution></institution-wrap>, Calgary, AB, Canada</aff><aff id="aff3-10732748251344481"><label>3</label>Leicester Cancer Research Centre, <institution-wrap><institution content-type="university">University of Leicester</institution></institution-wrap>, Leicester, UK</aff><aff id="aff4-10732748251344481"><label>4</label>Department of Medicine, Cumming School of Medicine, <institution-wrap><institution content-type="university">University of Calgary</institution></institution-wrap>, Calgary, AB, Canada</aff><aff id="aff5-10732748251344481"><label>5</label>Department of Community Health Sciences, Cumming School of Medicine, <institution-wrap><institution content-type="university">University of Calgary</institution></institution-wrap>, Calgary, AB, Canada</aff></contrib-group><author-notes><corresp id="corresp1-10732748251344481">Darren R. Brenner, PhD, Department of Oncology, Cumming School of Medicine, University of Calgary, 3330 Hospital Dr NW, Calgary, AB T2N 4N1, Canada. Email: <email>darren.brenner@ucalgary.ca</email></corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><season>Jan-Dec</season><year>2025</year></pub-date><volume>32</volume><elocation-id>10732748251344481</elocation-id><history><date date-type="received"><day>22</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>22</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>6</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder content-type="sage">SAGE Publications Inc, unless otherwise noted. Manuscript content on this site is licensed under Creative Common Licences</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><self-uri content-type="pdf" xlink:href="10.1177_10732748251344481.pdf"/><abstract><sec><title>Background</title><p>Colorectal cancer (CRC) is the third most diagnosed cancer and the second leading cause of cancer-related death worldwide. Colorectal adenomas (CRAs) are a crucial precursor for CRC and a target for preventive strategies. Recent network meta-analyses (NMAs) of randomized controlled trials (RCTs) suggest that chemopreventive agents (CPAs) are associated with reductions in CRC incidence. However, the quality of this evidence is low due to significant variability in the methods and types of studies assessed.</p></sec><sec><title>Purpose</title><p>Our study reviewed the efficacy and safety of CPAs on CRAs or CRCs evaluated in NMAs of RCTs and assessed the quality of all published NMAs on CPAs.</p></sec><sec><title>Research Design</title><p>We searched PubMed, Embase, and Cochrane Library for studies published from inception to July 29, 2024. We included all NMAs assessing the efficacy and safety of CPAs on CRC in both average-risk (general population) and high-risk (previous history of adenoma/CRC) populations. </p></sec><sec><title>Results</title><p>Nine NMAs comparing 15 different interventions were included. Aspirin and non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) such as celecoxib were the most studied. Aspirin demonstrated efficacy against the development of any CRA and low-dose aspirin was consistently more protective than high-dose aspirin. However, the effect of aspirin against advanced CRA was not statistically significant. Concerns for long-term aspirin use included an increased risk of gastrointestinal bleeding and ulceration, but when evaluating all serious adverse events (SAEs), aspirin users did not have an increased risk compared to controls. Non-aspirin NSAIDs showed better efficacy against advanced CRA. However, the use of non-aspirin NSAIDs such as celecoxib was associated with significantly increased risk of SAEs, particularly cardiovascular disease events.</p></sec><sec><title>Conclusions</title><p>Considering the balance of efficacy and safety, low-dose aspirin is currently the best option for chemoprevention of CRA/CRC. Future research is needed to better characterize the patient subgroups that benefit most and to develop new, more effective CPAs.</p></sec></abstract><kwd-group><kwd>colorectal cancer</kwd><kwd>colorectal adenoma</kwd><kwd>chemoprevention</kwd><kwd>preventive therapy</kwd><kwd>therapeutic prevention</kwd><kwd>chemopreventive agents</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>typesetter</meta-name><meta-value>ts10</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-10732748251344481"><title>Introduction</title><p>Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide.<sup>
<xref rid="bibr1-10732748251344481" ref-type="bibr">1</xref>
</sup> Approximately 1.9 million new diagnoses of CRC and roughly 900&#x000a0;000 CRC-related deaths were reported worldwide in 2022.<sup>
<xref rid="bibr1-10732748251344481" ref-type="bibr">1</xref>
</sup> Organized screening programs have led to substantial reductions in CRC incidence rates in recent years through the detection and removal of precancerous polyps, such as colorectal adenomas (CRAs).<sup><xref rid="bibr1-10732748251344481" ref-type="bibr">1</xref>-<xref rid="bibr4-10732748251344481" ref-type="bibr">4</xref></sup> CRAs are a crucial precursor for CRC and a target for preventive strategies.<sup>
<xref rid="bibr3-10732748251344481" ref-type="bibr">3</xref>
</sup> Chemoprevention, a term that is increasingly preferred as &#x0201c;preventive therapy&#x0201d;, or &#x0201c;therapeutic prevention&#x0201d;, refers to the use of certain agents or substances to reduce a person&#x02019;s risk of developing a disease.<sup>
<xref rid="bibr5-10732748251344481" ref-type="bibr">5</xref>
</sup> Recent advances in CRC chemoprevention have focused on leveraging repurposed pharmacological agents and dietary interventions to reduce the burden of CRC beyond screening.<sup>
<xref rid="bibr6-10732748251344481" ref-type="bibr">6</xref>
</sup> A published umbrella review of existing systematic reviews and meta-analyses on chemoprevention for CRC suggest that CRC chemopreventive agents (CPAs), such as aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), magnesium, and folate are associated with reductions in CRC incidence.<sup>
<xref rid="bibr6-10732748251344481" ref-type="bibr">6</xref>
</sup> However, the quality of this evidence is low as the studies assessed demonstrated substantial heterogeneity in their methods and study types.<sup>
<xref rid="bibr6-10732748251344481" ref-type="bibr">6</xref>
</sup> Furthermore, traditional meta-analysis only makes direct comparison of two interventions. Indirect comparisons and ranking of multiple interventions are not feasible with pairwise meta-analysis.</p><p>Network meta-analysis (NMA) of randomized controlled trials (RCTs) as an approach to synthesizing evidence is highly valuable when multiple interventions are compared. Compared to a traditional meta-analysis, NMA allows multiple intervention comparisons even when two interventions have not been directly compared in any RCTs.<sup>
<xref rid="bibr7-10732748251344481" ref-type="bibr">7</xref>
</sup> However, for these indirect comparisons to be valid, two key assumptions must be held. First, the effect modifiers of the relative intervention effects, for example, patient characteristics, must be similar across trials of different interventions. Second, the intervention effect estimates for a particular pairwise comparison must be consistent between the direct and indirect comparisons.<sup><xref rid="bibr7-10732748251344481" ref-type="bibr">7</xref>,<xref rid="bibr8-10732748251344481" ref-type="bibr">8</xref></sup> Otherwise, NMA are like traditional meta-analyses in methods, can be performed with fixed- or random-effects models, and within a frequentist or Bayesian framework. In this study, we aimed to review the efficacy and safety of all CPAs on CRAs or CRCs that have been evaluated in NMAs of RCTs. We also aimed to assess the quality of all published NMAs on CPAs.</p></sec><sec sec-type="methods" id="sec2-10732748251344481"><title>Methods</title><sec id="sec3-10732748251344481"><title>Search Strategy</title><p>We identified relevant studies through a systematic search of PubMed, Embase, and Cochrane Library databases using the search strategy as illustrated in <ext-link xlink:href="https://journals.sagepub.com/doi/supp/10.1177/10732748251344481" ext-link-type="uri">Table S1</ext-link>. The search was restricted to studies published from inception to July 29, 2024.</p></sec><sec id="sec4-10732748251344481"><title>Study Selection and Patient Population</title><p>Our selected studies included all NMAs assessing the efficacy and safety of CPAs on CRAs or CRCs in both average-risk (general population) and high-risk (previous history of adenoma/CRC) populations. The following inclusion criteria were applied in selecting studies: (1) Published studies of network meta-analysis on chemopreventive agents; (2) Study population was either &#x02018;high-risk&#x02019; patients with previous history of CRC or advanced CRA (adenoma &#x02265;10&#x000a0;mm, with tubulovillous or villous histology, or with high-grade dysplasia), regardless of whether they have genetic predisposition of CRC, or &#x02018;average-risk&#x02019; individuals with no history of CRC or advanced CRA; (3) Outcomes were the risk ratios (RRs) of the detection rate of CRC, advanced CRAs, or any CRAs, and of the adverse event (AE) rate. (<ext-link xlink:href="https://journals.sagepub.com/doi/supp/10.1177/10732748251344481" ext-link-type="uri">Table S2</ext-link>)</p></sec></sec><sec sec-type="results" id="sec5-10732748251344481"><title>Results</title><p>The initial search resulted in 79 studies eligible for abstract screening. 69 studies did not pass screening because they were either not NMA or NMA on topics not related to chemoprevention. Among the ten NMAs that were relevant to chemoprevention of recurrent CRA/CRC, one was excluded because it included observational studies, and the outcome included tumor markers instead of endoscopically confirmed adenomas or cancer,<sup>
<xref rid="bibr9-10732748251344481" ref-type="bibr">9</xref>
</sup> resulting in nine NMAs included in the final analysis (<xref rid="fig1-10732748251344481" ref-type="fig">Figure 1</xref>). An overview of the included NMAs is summarized in <xref rid="table1-10732748251344481" ref-type="table">Table 1</xref>. All NMAs were published between 2016 and 2024, including eligible RCTs from 1999 to 2022. As there is currently no tool to evaluate the quality of NMA, we included three metrics to indicate whether the NMA has used GRADE or ROB to assess the RCTs, has performed test of consistency, and has conducted sensitivity analysis (<xref rid="table1-10732748251344481" ref-type="table">Table 1</xref>). Most NMAs focused on recurrent CRAs among high-risk individuals with previous CRAs or CRCs, while two NMAs also studied the chemoprevention effect on the general population with average risk.<sup><xref rid="bibr10-10732748251344481" ref-type="bibr">10</xref>,<xref rid="bibr11-10732748251344481" ref-type="bibr">11</xref></sup> One NMA included both high-risk and average risk population, as well as subjects with Lynch syndrome or familial adenomatous polyposis.<sup>
<xref rid="bibr12-10732748251344481" ref-type="bibr">12</xref>
</sup> A total of 25 interventions (with different doses of aspirin and combination of CPAs as individual interventions) were assessed among all NMAs. We focused on 15 interventions that were included in at least two NMAs (<xref rid="table2-10732748251344481" ref-type="table">Table 2</xref>).<fig position="float" fig-type="figure" id="fig1-10732748251344481"><label>Figure 1.</label><caption><p>PRISMA Diagram.</p></caption><graphic xlink:href="10.1177_10732748251344481-fig1" position="float"/></fig><table-wrap position="float" id="table1-10732748251344481"><label>Table 1.</label><caption><p>Summary of the Included Network Meta-Analysis (NMAs).</p></caption><alternatives><graphic xlink:href="10.1177_10732748251344481-table1" specific-use="table1-10732748251344481" position="float"/><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1"><break/>First Author</th><th align="center" rowspan="1" colspan="1">Country<break/>/origin of institute</th><th align="center" rowspan="1" colspan="1">Title</th><th align="center" rowspan="1" colspan="1">Publication Year</th><th align="center" rowspan="1" colspan="1">Study year span</th><th align="center" rowspan="1" colspan="1">No. RCT included</th><th align="center" rowspan="1" colspan="1">No. Interventions</th><th align="center" rowspan="1" colspan="1">No. Pts</th><th align="center" rowspan="1" colspan="1">Statistical framework</th><th align="center" rowspan="1" colspan="1">Population characteristics</th><th align="center" rowspan="1" colspan="1">Outcome</th><th align="center" rowspan="1" colspan="1">GRADE/ROB</th><th align="center" rowspan="1" colspan="1">Evaluation of consistency</th><th align="center" rowspan="1" colspan="1">Sensitivity analysis</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">Dulai, P.</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: Systematic review and network meta-analysis</td><td align="left" rowspan="1" colspan="1">2016</td><td align="char" char="-" rowspan="1" colspan="1">1999-2015</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">12&#x000a0;234</td><td align="left" rowspan="1" colspan="1">Bayesian</td><td align="left" rowspan="1" colspan="1">High risk</td><td align="left" rowspan="1" colspan="1">Adv. Neoplasia</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Y</td></tr><tr><td align="left" rowspan="1" colspan="1">Veettil, S.</td><td align="left" rowspan="1" colspan="1">Malaysia</td><td align="left" rowspan="1" colspan="1">Effects of chemopreventive agents on the incidence of recurrent colorectal adenomas: a Systematic review with network meta-analysis of randomized controlled trials</td><td align="left" rowspan="1" colspan="1">2017</td><td align="char" char="-" rowspan="1" colspan="1">1988-2016</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">12&#x000a0;625</td><td align="left" rowspan="1" colspan="1">Frequentist</td><td align="left" rowspan="1" colspan="1">High risk</td><td align="left" rowspan="1" colspan="1">Any adenoma; Adv. Adenoma</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Y</td></tr><tr><td align="left" rowspan="1" colspan="1">Veettil, S.</td><td align="left" rowspan="1" colspan="1">Malaysia</td><td align="left" rowspan="1" colspan="1">Efficacy and safety of chemopreventive agents on colorectal cancer incidence and mortality: Systematic review and network meta-analysis</td><td align="left" rowspan="1" colspan="1">2018</td><td align="char" char="-" rowspan="1" colspan="1">1988-2013</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">281&#x000a0;063</td><td align="left" rowspan="1" colspan="1">Frequentist</td><td align="left" rowspan="1" colspan="1">General population</td><td align="left" rowspan="1" colspan="1">CRC (0-10y); CRC (10-20y)</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Y</td></tr><tr><td align="left" rowspan="1" colspan="1">Veettil, S.</td><td align="left" rowspan="1" colspan="1">Malaysia</td><td align="left" rowspan="1" colspan="1">Very low dose aspirin and surveillance colonoscopy is cost effective in secondary<break/>Prevention of colorectal cancer in individuals<break/>with advanced adenomas: Network<break/>metaanalysis and cost effectiveness analysis</td><td align="left" rowspan="1" colspan="1">2021</td><td align="char" char="-" rowspan="1" colspan="1">1999-2018</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">NR</td><td align="left" rowspan="1" colspan="1">Frequentist</td><td align="left" rowspan="1" colspan="1">High risk</td><td align="left" rowspan="1" colspan="1">Adv. Adenoma</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Y</td></tr><tr><td align="left" rowspan="1" colspan="1">Heer, E.</td><td align="left" rowspan="1" colspan="1">Canada</td><td align="left" rowspan="1" colspan="1">The efficacy of chemopreventive agents on the incidence of colorectal adenomas: A systematic review and network meta-analysis</td><td align="left" rowspan="1" colspan="1">2022</td><td align="char" char="-" rowspan="1" colspan="1">1988-2019</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">20&#x000a0;925</td><td align="left" rowspan="1" colspan="1">Bayesian</td><td align="left" rowspan="1" colspan="1">High risk</td><td align="left" rowspan="1" colspan="1">Any adenoma; Adv. Adenoma</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Y</td></tr><tr><td align="left" rowspan="1" colspan="1">Shah, D.</td><td align="left" rowspan="1" colspan="1">Australia</td><td align="left" rowspan="1" colspan="1">Aspirin chemoprevention in colorectal cancer: network meta-analysis of low, moderate, and high doses</td><td align="left" rowspan="1" colspan="1">2023</td><td align="char" char="-" rowspan="1" colspan="1">1998-2018</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">92&#x000a0;550</td><td align="left" rowspan="1" colspan="1">Bayesian</td><td align="left" rowspan="1" colspan="1">High risk</td><td align="left" rowspan="1" colspan="1">CRC</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">N</td></tr><tr><td align="left" rowspan="1" colspan="1">Ma, Y</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">Chemoprevention of colorectal cancer in general population and high-risk population: a Systematic review and network meta-analysis</td><td align="left" rowspan="1" colspan="1">2023</td><td align="char" char="-" rowspan="1" colspan="1">1993-2021</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">278&#x000a0;694</td><td align="left" rowspan="1" colspan="1">Frequentist</td><td align="left" rowspan="1" colspan="1">General population; High risk</td><td align="left" rowspan="1" colspan="1">Any adenoma; Adv. Adenoma; CRC</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Y</td></tr><tr><td align="left" rowspan="1" colspan="1">Hoang, K</td><td align="left" rowspan="1" colspan="1">Taiwan</td><td align="left" rowspan="1" colspan="1">Oral aspirin for preventing colorectal adenoma recurrence: A systematic review<break/>and network meta-analysis of randomized<break/>controlled trials</td><td align="left" rowspan="1" colspan="1">2024</td><td align="char" char="-" rowspan="1" colspan="1">2003-2021</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">3011</td><td align="left" rowspan="1" colspan="1">Frequentist</td><td align="left" rowspan="1" colspan="1">High risk</td><td align="left" rowspan="1" colspan="1">Any adenoma</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Y</td></tr><tr><td align="left" rowspan="1" colspan="1">Tan</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">Preventive effects of chemical drugs on recurrence of colorectal adenomas: Systematic review and Bayesian network meta-analysis</td><td align="left" rowspan="1" colspan="1">2024</td><td align="char" char="-" rowspan="1" colspan="1">2000-2022</td><td align="left" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">35&#x000a0;590</td><td align="left" rowspan="1" colspan="1">Bayesian</td><td align="left" rowspan="1" colspan="1">High risk</td><td align="left" rowspan="1" colspan="1">Any adenoma</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">Y</td><td align="left" rowspan="1" colspan="1">N</td></tr></tbody></table></alternatives></table-wrap><table-wrap position="float" id="table2-10732748251344481"><label>Table 2.</label><caption><p>Efficacy of Chemopreventive Agents (CPAs).</p></caption><alternatives><graphic xlink:href="10.1177_10732748251344481-table2" specific-use="table2-10732748251344481" position="float"/><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1"><break/>Outcome</th><th align="center" rowspan="1" colspan="1">First Author</th><th align="center" rowspan="1" colspan="1">Publication Year</th><th align="center" rowspan="1" colspan="1">Population characteristics</th><th align="center" rowspan="1" colspan="1">NSAID (non-ASA)</th><th align="center" rowspan="1" colspan="1">DFMO + Sulindac</th><th align="center" rowspan="1" colspan="1">VLD-ASA</th><th align="center" rowspan="1" colspan="1">LD-ASA</th><th align="center" rowspan="1" colspan="1">HD-ASA</th><th align="center" rowspan="1" colspan="1">ASA, any dose</th><th align="center" rowspan="1" colspan="1">Calcium</th><th align="center" rowspan="1" colspan="1">Vitamin D</th><th align="center" rowspan="1" colspan="1">Calcium + Vitamin D</th><th align="center" rowspan="1" colspan="1">ASA + Calcium + Vitamin D</th><th align="center" rowspan="1" colspan="1">Folate/folic acid</th><th align="center" rowspan="1" colspan="1">ASA + Folate</th><th align="center" rowspan="1" colspan="1">Antioxidant</th><th align="center" rowspan="1" colspan="1">Berberine</th><th align="center" rowspan="1" colspan="1">UDCA</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="7" colspan="1">Any adenoma</td><td align="left" rowspan="2" colspan="1">Veettil, S.</td><td align="left" rowspan="2" colspan="1">2017</td><td align="left" rowspan="2" colspan="1">High risk</td><td align="left" rowspan="1" colspan="1">CEL400: 0.70 (0.64, 0.76)</td><td align="left" rowspan="2" colspan="1"/><td align="left" rowspan="2" colspan="1"/><td align="left" rowspan="2" colspan="1">0.83 (0.70, 0.99)</td><td align="left" rowspan="2" colspan="1">0.93 (0.67, 1.29)</td><td align="left" rowspan="2" colspan="1"/><td align="left" rowspan="2" colspan="1">0.83 (0.75, 0.93)</td><td align="left" rowspan="2" colspan="1">0.98 (0.84, 1.13)</td><td align="left" rowspan="2" colspan="1">0.86 (0.66, 1.12)</td><td align="left" rowspan="2" colspan="1">0.94 (0.60, 1.45)</td><td align="left" rowspan="2" colspan="1">1.06 (0.87, 1.28)</td><td align="left" rowspan="2" colspan="1">0.91 (0.70, 1.19)</td><td align="left" rowspan="2" colspan="1">0.77 (0.54, 1.11)</td><td align="left" rowspan="2" colspan="1"/><td align="left" rowspan="2" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CEL800: 0.62 (0.55, 0.69)</td></tr><tr><td align="left" rowspan="1" colspan="1">Heer, E.</td><td align="left" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">High risk</td><td align="left" rowspan="1" colspan="1">CEL: 0.71 (0.48, 1.04)</td><td align="left" rowspan="1" colspan="1">0.24 (0.10, 0.55)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.69 (0.52, 0.91)</td><td align="left" rowspan="1" colspan="1">0.85 (0.69, 1.05)</td><td align="left" rowspan="1" colspan="1">0.77 (0.59, 1.00)</td><td align="left" rowspan="1" colspan="1">0.78 (0.56, 1.08)</td><td align="left" rowspan="1" colspan="1">0.91 (0.58, 1.39)</td><td align="left" rowspan="1" colspan="1">0.87 (0.56, 1.33)</td><td align="left" rowspan="1" colspan="1">0.94 (0.54, 1.64)</td><td align="left" rowspan="1" colspan="1">1.08 (0.79, 1.49)</td><td align="left" rowspan="1" colspan="1">HD: 0.82 (0.51, 1.33)</td><td align="left" rowspan="1" colspan="1">0.84 (0.63, 1.07)</td><td align="left" rowspan="1" colspan="1">0.72 (0.37, 1.40)</td><td align="left" rowspan="1" colspan="1">0.90 (0.46, 1.74)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ma, Y</td><td align="left" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">Avg risk</td><td align="left" rowspan="1" colspan="1">0.59 (0.44, 0.79)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.69 (0.42, 1.13)</td><td align="left" rowspan="1" colspan="1">0.88 (1.64, 1.20)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.88 (0.55, 1.41)</td><td align="left" rowspan="1" colspan="1">1.02 (0.70, 1.50)</td><td align="left" rowspan="1" colspan="1">0.93 (0.50, 1.74)</td><td align="left" rowspan="1" colspan="1">0.91 (0.43, 1.94)</td><td align="left" rowspan="1" colspan="1">0.90 (0.66, 1.22)</td><td align="left" rowspan="1" colspan="1">0.76 (0.40, 1.44)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.89 (0.46, 1.71)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ma, Y</td><td align="left" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">High risk</td><td align="left" rowspan="1" colspan="1">0.58 (0.43, 0.79)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.70 (0.45, 1.11)</td><td align="left" rowspan="1" colspan="1">0.91 (0.66, 1.27)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.92 (0.59, 1.44)</td><td align="left" rowspan="1" colspan="1">1.21 (0.65, 2.23)</td><td align="left" rowspan="1" colspan="1">1.00 (0.54, 1.84)</td><td align="left" rowspan="1" colspan="1">0.91 (0.46, 1.83)</td><td align="left" rowspan="1" colspan="1">1.13 (0.78, 1.63)</td><td align="left" rowspan="1" colspan="1">0.83 (0.46, 1.51)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.89 (0.49, 1.59)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hoang, K</td><td align="left" rowspan="1" colspan="1">2024</td><td align="left" rowspan="1" colspan="1">High risk</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.70 (0.54, 0.91)</td><td align="left" rowspan="1" colspan="1">0.92 (0.77, 1.10)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Tan</td><td align="left" rowspan="1" colspan="1">2024</td><td align="left" rowspan="1" colspan="1">High risk</td><td align="left" rowspan="1" colspan="1">0.84 (0.76, 0.92)</td><td align="left" rowspan="1" colspan="1">0.34 (0.25, 0.44)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.90 (0.84, 0.96)</td><td align="left" rowspan="1" colspan="1">0.94 (0.90, 1.01)</td><td align="left" rowspan="1" colspan="1">1.02 (0.97, 1.09)</td><td align="left" rowspan="1" colspan="1">0.98 (0.92, 1.05)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.89 (0.79, 0.98)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.98 (0.94, 1.01)</td><td align="left" rowspan="1" colspan="1">0.79 (0.68, 0.92)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="6" colspan="1">Adv. Adenoma</td><td align="left" rowspan="2" colspan="1">Veettil, S.</td><td align="left" rowspan="2" colspan="1">2017</td><td align="left" rowspan="2" colspan="1">High risk</td><td align="left" rowspan="1" colspan="1">CEL400: 0.48 (0.38, 0.60)</td><td align="left" rowspan="2" colspan="1"/><td align="left" rowspan="2" colspan="1"/><td align="left" rowspan="2" colspan="1">0.84 (0.46, 1.55)</td><td align="left" rowspan="2" colspan="1">0.88 (0.61, 1.25)</td><td align="left" rowspan="2" colspan="1"/><td align="left" rowspan="2" colspan="1">1.01 (0.74, 1.38)</td><td align="left" rowspan="2" colspan="1">1.19 (0.78, 1.82)</td><td align="left" rowspan="2" colspan="1">0.95 (0.66, 1.37)</td><td align="left" rowspan="2" colspan="1"/><td align="left" rowspan="2" colspan="1">1.21 (0.82, 1.78)</td><td align="left" rowspan="1" colspan="1">LD: 0.54 (0.28, 1.02)</td><td align="left" rowspan="2" colspan="1">0.45 (0.16, 1.23)</td><td align="left" rowspan="2" colspan="1"/><td align="left" rowspan="2" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CEL800: 0.37 (0.26, 0.51)</td><td align="left" rowspan="1" colspan="1">HD: 0.81 (0.55, 1.19)</td></tr><tr><td align="left" rowspan="2" colspan="1">Veettil, S.</td><td align="left" rowspan="2" colspan="1">2021</td><td align="left" rowspan="2" colspan="1">High risk</td><td align="left" rowspan="1" colspan="1">CEL400: 0.45 (0.35, 0.58)</td><td align="left" rowspan="2" colspan="1"/><td align="left" rowspan="2" colspan="1">0.49 (0.31, 0.78)</td><td align="left" rowspan="2" colspan="1">0.79 (0.63, 1.00)</td><td align="left" rowspan="2" colspan="1"/><td align="left" rowspan="2" colspan="1"/><td align="left" rowspan="2" colspan="1">1.00 (0.74, 1.35)</td><td align="left" rowspan="2" colspan="1">1.17 (0.79, 1.73)</td><td align="left" rowspan="2" colspan="1">0.92 (0.64,1.33)</td><td align="left" rowspan="2" colspan="1">0.75 (0.24, 2.31)</td><td align="left" rowspan="2" colspan="1"/><td align="left" rowspan="2" colspan="1"/><td align="left" rowspan="2" colspan="1"/><td align="left" rowspan="2" colspan="1"/><td align="left" rowspan="2" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CEL800: 0.36 (0.25, 0.52)</td></tr><tr><td align="left" rowspan="1" colspan="1">Heer, E.</td><td align="left" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">High risk</td><td align="left" rowspan="1" colspan="1">CEL: 0.51 (0.25, 0.88)</td><td align="left" rowspan="1" colspan="1">0.06 (0.00, 0.40)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.57 (0.30, 1.06)</td><td align="left" rowspan="1" colspan="1">0.82 (0.56, 1.18)</td><td align="left" rowspan="1" colspan="1">0.73 (0.37, 1.25)</td><td align="left" rowspan="1" colspan="1">1.24 (0.64, 2.45)</td><td align="left" rowspan="1" colspan="1">1.20 (0.61, 2.33)</td><td align="left" rowspan="1" colspan="1">1.03 (0.52, 2.02)</td><td align="left" rowspan="1" colspan="1">0.76 (0.20, 2.72)</td><td align="left" rowspan="1" colspan="1">1.25 (0.81, 1.90)</td><td align="left" rowspan="1" colspan="1">HD: 0.64 (0.32, 1.24)</td><td align="left" rowspan="1" colspan="1">1.09 (0.49, 2.27)</td><td align="left" rowspan="1" colspan="1">0.57 (0.20, 1.48)</td><td align="left" rowspan="1" colspan="1">0.80 (0.36, 1.66)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ma, Y</td><td align="left" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">Avg risk</td><td align="left" rowspan="1" colspan="1">0.63 (0.43, 0.92)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.72 (0.42, 1.24)</td><td align="left" rowspan="1" colspan="1">0.76 (0.51, 1.13)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.94 (0.57, 1.54)</td><td align="left" rowspan="1" colspan="1">1.04 (0.51, 2.12)</td><td align="left" rowspan="1" colspan="1">0.87 (0.42, 1.79)</td><td align="left" rowspan="1" colspan="1">0.74 (0.21, 2.63)</td><td align="left" rowspan="1" colspan="1">1.06 (0.75, 1.49)</td><td align="left" rowspan="1" colspan="1">0.58 (0.29, 1.17)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.82 (0.45, 1.48)</td></tr><tr><td align="left" rowspan="1" colspan="1">Adv. Neoplasia</td><td align="left" rowspan="1" colspan="1">Dulai, P.</td><td align="left" rowspan="1" colspan="1">2016</td><td align="left" rowspan="1" colspan="1">High risk</td><td align="left" rowspan="1" colspan="1">0.37 (0.24-0.53)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.71 (0.41, 1.23)</td><td align="left" rowspan="1" colspan="1">1.12 (0.59, 2.10)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.00 (0.66, 1.52)</td><td align="left" rowspan="1" colspan="1">1.19 (0.65, 2.15)</td><td align="left" rowspan="1" colspan="1">0.91 (0.52, 1.63)</td><td align="left" rowspan="1" colspan="1">0.71 (0.18, 2.49)</td><td align="left" rowspan="1" colspan="1">1.32 (0.85, 2.00)</td><td align="left" rowspan="1" colspan="1">0.73 (0.43, 1.19)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CRC (0-10y)</td><td align="left" rowspan="1" colspan="1">Veettil, S.</td><td align="left" rowspan="1" colspan="1">2018</td><td align="left" rowspan="1" colspan="1">Avg risk</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.89 (0.63, 1.26)</td><td align="left" rowspan="1" colspan="1">1.15 (0.75, 1.74)</td><td align="left" rowspan="1" colspan="1">0.91 (0.55, 1.53)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.19 (0.01, 3.60)</td><td align="left" rowspan="1" colspan="1">1.03 (0.59, 1.82)</td><td align="left" rowspan="1" colspan="1">1.06 (0.78,1.44)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.00 (0.14, 7.14)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.94 (0.81, 1.10)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CRC (10-20y)</td><td align="left" rowspan="1" colspan="1">Veettil, S.</td><td align="left" rowspan="1" colspan="1">2018</td><td align="left" rowspan="1" colspan="1">Avg risk</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.81 (0.67, 0.98)</td><td align="left" rowspan="1" colspan="1">1.03 (0.83, 1.27)</td><td align="left" rowspan="1" colspan="1">0.74 (0.57, 0.97)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.96 [0.81, 1.13]</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.07 (0.89,1.28)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CRC</td><td align="left" rowspan="1" colspan="1">Shah, D.</td><td align="left" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">Mixed risk</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.95 (0.78, 1.16)</td><td align="left" rowspan="1" colspan="1">0.73 (0.25, 2.08)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CRC</td><td align="left" rowspan="1" colspan="1">Ma, Y</td><td align="left" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">Avg risk</td><td align="left" rowspan="1" colspan="1">0.68 (0.28, 1.62)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.21 (0.83, 1.75)</td><td align="left" rowspan="1" colspan="1">1.03 (0.58, 1.83)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.09 (0.56, 2.12)</td><td align="left" rowspan="1" colspan="1">1.09 (0.61, 1.94)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.34 (0.78, 2.32)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn><p>Footnote: Antioxidants include any interventions with vitamin A, B6, B12, C, and E, &#x003b1;-tocopherol, beta-carotene, selenium, green tea extracts, either as single agent or as combinations.</p></fn><fn><p>Abbreviations: Adv, advanced; ASA, Acetylsalicylic acid (aspirin); Avg, average; CPA, chemopreventive agent; CRC, colorectal cancer; DFMO, difluoromethylornithine; HD, high-dose; LD, low-dose; NSAID, non-steroidal anti-inflammatory drug; UDCA, ursodeoxycholic acid; VLD, very low-dose.</p></fn></table-wrap-foot></table-wrap></p><p>Aspirin was the most studied agent for preventing CRAs. All nine NMAs included aspirin in their analyses. Most NMAs presented odds ratios (ORs) for aspirin by low (80 &#x02013; 160&#x000a0;mg/day) or high (160 &#x02013; 325&#x000a0;mg/day) doses. For the incidence of any CRA, the protective effect of low-dose aspirin was consistently better than that of high-dose aspirin.<sup><xref rid="bibr11-10732748251344481" ref-type="bibr">11</xref>,<xref rid="bibr13-10732748251344481" ref-type="bibr">13</xref>-<xref rid="bibr15-10732748251344481" ref-type="bibr">15</xref></sup> However, in terms of advanced adenoma, all NMAs suggested that effect estimates were not statistically significant with either low- or high-dose aspirin intervention. Interestingly, one NMA showed that very low dose of aspirin (&#x0003c;100&#x000a0;mg/day) reduces the risk of advanced adenoma by 51% (RR: 0.49, 95% CI: 0.31-0.78).<sup>
<xref rid="bibr16-10732748251344481" ref-type="bibr">16</xref>
</sup> Three NMAs also investigated the effect of aspirin on preventing CRC. Aspirin did not reduce the risk of CRC among a mixed population of average risk, high risk, and individuals with genetic predisposition<sup>
<xref rid="bibr12-10732748251344481" ref-type="bibr">12</xref>
</sup> or among the average-risk population with less than 10&#x000a0;years of follow-up.<sup><xref rid="bibr10-10732748251344481" ref-type="bibr">10</xref>,<xref rid="bibr11-10732748251344481" ref-type="bibr">11</xref></sup> Among the general population with longer than 10&#x000a0;years of follow-up, both very low dose and high-dose aspirin demonstrated a significant protective effect.<sup>
<xref rid="bibr10-10732748251344481" ref-type="bibr">10</xref>
</sup> The major safety concern of long-term aspirin use was gastrointestinal (GI) bleeding and ulceration. A significantly increased risk was observed among both the high-risk individuals<sup>
<xref rid="bibr12-10732748251344481" ref-type="bibr">12</xref>
</sup> or the general population<sup>
<xref rid="bibr10-10732748251344481" ref-type="bibr">10</xref>
</sup> in a dose-dependent manner. On the other hand, when looking at all serious AEs, including GI bleeding, cardiovascular or non-cardiovascular complications, hospitalization, and death, aspirin users did not have increased risk compared to the control group.<sup><xref rid="bibr11-10732748251344481" ref-type="bibr">11</xref>,<xref rid="bibr16-10732748251344481" ref-type="bibr">16</xref>,<xref rid="bibr17-10732748251344481" ref-type="bibr">17</xref></sup></p><p>Non-aspirin NSAIDs, such as cyclooxygenase-2 (Cox-2) inhibitors and sulindac, are an important family of agents for preventing CRAs. Six NMAs included non-aspirin NSAIDs, all of which were on high-risk individuals with a history of adenoma or CRC<sup><xref rid="bibr11-10732748251344481" ref-type="bibr">11</xref>,<xref rid="bibr13-10732748251344481" ref-type="bibr">13</xref>,<xref rid="bibr14-10732748251344481" ref-type="bibr">14</xref>,<xref rid="bibr16-10732748251344481" ref-type="bibr">16</xref>-<xref rid="bibr18-10732748251344481" ref-type="bibr">18</xref></sup> and one NMA also provided effect estimates on the general population.<sup>
<xref rid="bibr11-10732748251344481" ref-type="bibr">11</xref>
</sup> Non-aspirin NSAIDs were consistently ranked among the most effective agents in preventing recurrent advanced adenoma.<sup><xref rid="bibr11-10732748251344481" ref-type="bibr">11</xref>,<xref rid="bibr13-10732748251344481" ref-type="bibr">13</xref>,<xref rid="bibr14-10732748251344481" ref-type="bibr">14</xref>,<xref rid="bibr16-10732748251344481" ref-type="bibr">16</xref>,<xref rid="bibr17-10732748251344481" ref-type="bibr">17</xref></sup> In terms of any CRA, the RRs of non-aspirin NSAIDs were less consistent, ranging from 0.59<sup>11</sup> to 0.84.<sup>
<xref rid="bibr18-10732748251344481" ref-type="bibr">18</xref>
</sup> Two NMAs observed the strongest prevention effect with a combination of difluoromethylornithine and sulindac.<sup><xref rid="bibr14-10732748251344481" ref-type="bibr">14</xref>,<xref rid="bibr18-10732748251344481" ref-type="bibr">18</xref></sup> However, it was based on one RCT with moderate to high risk of bias.<sup>
<xref rid="bibr19-10732748251344481" ref-type="bibr">19</xref>
</sup> The safety of non-aspirin NSAIDs was a concern for long-term use. An estimated 20-30% of increased risk of serious AEs was found in three NMAs.<sup><xref rid="bibr11-10732748251344481" ref-type="bibr">11</xref>,<xref rid="bibr16-10732748251344481" ref-type="bibr">16</xref>,<xref rid="bibr17-10732748251344481" ref-type="bibr">17</xref></sup> The risk of cardiovascular and thrombotic AEs with long-term use of non-aspirin NSAIDs is particularly elevated in patients with pre-existing atherosclerotic heart diseases.<sup>
<xref rid="bibr20-10732748251344481" ref-type="bibr">20</xref>
</sup></p><p>Observational studies have observed a link between low levels of dietary calcium and an increased risk of CRC,<sup>
<xref rid="bibr21-10732748251344481" ref-type="bibr">21</xref>
</sup> and between higher vitamin D levels and a reduced risk of CRC.<sup>
<xref rid="bibr22-10732748251344481" ref-type="bibr">22</xref>
</sup> Therefore, it was suggested that increasing calcium intake and/or vitamin D supplementation may lower the risk for recurrent CRA. However, except for one NMA which reported a 17% decreased risk of any CRA (RR: 0.83, 95% CI: 0.75-0.93),<sup>
<xref rid="bibr13-10732748251344481" ref-type="bibr">13</xref>
</sup> no protective effects of calcium and vitamin D supplementation, alone or in combination, were observed among the high-risk individuals.<sup><xref rid="bibr11-10732748251344481" ref-type="bibr">11</xref>,<xref rid="bibr13-10732748251344481" ref-type="bibr">13</xref>,<xref rid="bibr14-10732748251344481" ref-type="bibr">14</xref>,<xref rid="bibr16-10732748251344481" ref-type="bibr">16</xref>-<xref rid="bibr18-10732748251344481" ref-type="bibr">18</xref></sup> Calcium and vitamin D had no effects on CRA or CRC either among the general population.<sup><xref rid="bibr10-10732748251344481" ref-type="bibr">10</xref>,<xref rid="bibr11-10732748251344481" ref-type="bibr">11</xref></sup> Although calcium ranked the top agent in reducing early risk of CRC in one NMA,<sup>
<xref rid="bibr10-10732748251344481" ref-type="bibr">10</xref>
</sup> the confidence interval (CI) was extremely wide, indicating very high uncertainty (RR: 0.19, 95% CI: 0.01-3.60). In addition, five NMAs reported the combination of calcium, vitamin D, and aspirin among high-risk individuals.<sup><xref rid="bibr11-10732748251344481" ref-type="bibr">11</xref>,<xref rid="bibr13-10732748251344481" ref-type="bibr">13</xref>,<xref rid="bibr14-10732748251344481" ref-type="bibr">14</xref>,<xref rid="bibr16-10732748251344481" ref-type="bibr">16</xref>,<xref rid="bibr17-10732748251344481" ref-type="bibr">17</xref></sup> The effect estimates were similar to those of aspirin alone. It should be noted that although individual RCTs may account for baseline level of calcium or vitamin D among the participants, it was not possible to adjust for this variable in NMAs. There might be a protective effect among individuals with deficiency of calcium or vitamin D. Surprisingly, the safety of calcium supplementation among high-risk individuals seemed to be questionable. Among four NMAs reporting the AEs for calcium, two reported 38% and 22% increased risk of serious AEs, including death, hospital admission, severe gastrointestinal bleeding, vascular complications, or discontinuation of treatment due to serious or severe events, which were statistically significant.<sup><xref rid="bibr16-10732748251344481" ref-type="bibr">16</xref>,<xref rid="bibr17-10732748251344481" ref-type="bibr">17</xref></sup> However, no increased risk was observed for vitamin D or the combination of calcium and vitamin D.<sup><xref rid="bibr11-10732748251344481" ref-type="bibr">11</xref>,<xref rid="bibr16-10732748251344481" ref-type="bibr">16</xref>-<xref rid="bibr18-10732748251344481" ref-type="bibr">18</xref></sup></p><p>Folate and folic acid have been controversial in the association with CRC. While observational studies suggested that higher folate intake was associated with reduced risk of CRC, RCTs did not find a beneficial role in CRC and even a possible increase in CRA.<sup>
<xref rid="bibr23-10732748251344481" ref-type="bibr">23</xref>
</sup> Folate also potentially interferes with chemotherapy among CRC patients undergoing active therapy.<sup>
<xref rid="bibr24-10732748251344481" ref-type="bibr">24</xref>
</sup> Chemotherapeutical drug fluoropyrimidines, such as 5-fluorouracil (5-FU) or capecitabine, primarily target thymidylate synthase (TS), a key enzyme in nucleotide biosynthesis and folate metabolism. Therefore, intermediate folate derivatives may form a stable complex with TS and 5-FU and influence the TS inhibition rate. Observational studies have shown that higher serum level of folate during chemotherapy was associated with a higher risk of toxicity.<sup>
<xref rid="bibr24-10732748251344481" ref-type="bibr">24</xref>
</sup> The lack of preventive effect of folate in CRC or CRA was observed in most NMAs,<sup><xref rid="bibr10-10732748251344481" ref-type="bibr">10</xref>,<xref rid="bibr11-10732748251344481" ref-type="bibr">11</xref>,<xref rid="bibr13-10732748251344481" ref-type="bibr">13</xref>,<xref rid="bibr14-10732748251344481" ref-type="bibr">14</xref>,<xref rid="bibr17-10732748251344481" ref-type="bibr">17</xref></sup> except for the latest NMA, which reported a 11% reduction in any CRA (RR: 0.89, 95% CI: 0.79-0.98).<sup>
<xref rid="bibr18-10732748251344481" ref-type="bibr">18</xref>
</sup> The reason for this discrepancy is unclear. It is possible that the included RCTs for folate are different in this NMA, as the authors also reported a significantly higher risk of AEs (RR: 1.21, 95% CI: 1.08-1.35) in contrast to other NMAs (<xref rid="table3-10732748251344481" ref-type="table">Table 3</xref>).<table-wrap position="float" id="table3-10732748251344481"><label>Table 3.</label><caption><p>Safety of Chemopreventive Agents (CPAs).</p></caption><alternatives><graphic xlink:href="10.1177_10732748251344481-table3" specific-use="table3-10732748251344481" position="float"/><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1"><break/>First Author</th><th align="center" rowspan="1" colspan="1">Publication Year</th><th align="center" rowspan="1" colspan="1">Outcome</th><th align="center" rowspan="1" colspan="1">NSAID (non-ASA)</th><th align="center" rowspan="1" colspan="1">DFMO + Sulindac</th><th align="center" rowspan="1" colspan="1">VLD-ASA</th><th align="center" rowspan="1" colspan="1">LD-ASA</th><th align="center" rowspan="1" colspan="1">HD-ASA</th><th align="center" rowspan="1" colspan="1">ASA, any dose</th><th align="center" rowspan="1" colspan="1">Calcium</th><th align="center" rowspan="1" colspan="1">Vitamin D</th><th align="center" rowspan="1" colspan="1">Calcium + Vitamin D</th><th align="center" rowspan="1" colspan="1">ASA + Calcium + Vitamin D</th><th align="center" rowspan="1" colspan="1">Folate/folic acid</th><th align="center" rowspan="1" colspan="1">ASA + Folate</th><th align="center" rowspan="1" colspan="1">Antioxidant</th><th align="center" rowspan="1" colspan="1">Berberine</th><th align="center" rowspan="1" colspan="1">UDCA</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">Dulai, P.</td><td align="left" rowspan="1" colspan="1">2016</td><td align="left" rowspan="1" colspan="1">Serious adverse events*</td><td align="left" rowspan="1" colspan="1">1.23 (0.95, 1.64)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">0.78 (0.43, 1.38)</td><td align="char" char="(" rowspan="1" colspan="1">1.06 (0.76, 1.49)</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">1.38 (1.07, 1.89)</td><td align="char" char="(" rowspan="1" colspan="1">1.10 (0.74, 1.70)</td><td align="char" char="(" rowspan="1" colspan="1">1.11 (0.76, 1.70)</td><td align="char" char="(" rowspan="1" colspan="1">0.80 (0.54, 1.51)</td><td align="char" char="(" rowspan="1" colspan="1">0.85 (0.59, 1.22)</td><td align="char" char="(" rowspan="1" colspan="1">1.21 (0.83, 1.77)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Veettil, S.</td><td align="left" rowspan="1" colspan="1">2018</td><td align="left" rowspan="1" colspan="1">Major GI bleeding</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">1.44 (1.15, 1.81)</td><td align="char" char="(" rowspan="1" colspan="1">1.85 (1.22, 2.81)</td><td align="char" char="(" rowspan="1" colspan="1">4.04 (1.86, 8.76)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Veettil, S.</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">Serious adverse events*</td><td align="left" rowspan="1" colspan="1">CEL400: 1.16 (0.97,1.38)<break/>CEL800: 1.27 (1.00,1.62)</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">0.82 (0.47,1.41)</td><td align="char" char="(" rowspan="1" colspan="1">0.97 (0.78,1.21)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">1.22 (1.02,1.44)</td><td align="char" char="(" rowspan="1" colspan="1">1.05 (0.82,1.35)</td><td align="char" char="(" rowspan="1" colspan="1">1.07 (0.85,1.34)</td><td align="char" char="(" rowspan="1" colspan="1">0.92 (0.64, 1.32)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Shah, D.</td><td align="left" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">GI bleeding and ulceration</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">1.32 (1.09, 1.79)</td><td align="char" char="(" rowspan="1" colspan="1">1.64 (1.05, 2.56)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Ma, Y</td><td align="left" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">Serious adverse events**</td><td align="left" rowspan="1" colspan="1">1.29 (1.13, 1.47)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">0.95 (0.76, 1.19)</td><td align="char" char="(" rowspan="1" colspan="1">0.87 (0.57, 1.31)</td><td align="char" char="(" rowspan="1" colspan="1">1.06 (0.91, 1.24)</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">0.95 (0.57, 1.60)</td><td align="char" char="(" rowspan="1" colspan="1">1.10 (0.77, 1.56)</td><td align="char" char="(" rowspan="1" colspan="1">1.03 (0.56, 1.91)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Tan</td><td align="left" rowspan="1" colspan="1">2024</td><td align="left" rowspan="1" colspan="1">Adverse events***</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">3.19 (1.80, 6.45)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">1.11 (0.92, 1.32)</td><td align="char" char="(" rowspan="1" colspan="1">0.98 (0.85, 1.12)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">1.21 (1.08, 1.35)</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">1.13 (1.02, 1.23)</td><td align="char" char="(" rowspan="1" colspan="1">0.94 (0.43, 2.05)</td><td align="char" char="(" rowspan="1" colspan="1">1.01 (0.63, 1.45)</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>*Defined as events resulting in death, admission to hospital related to an adverse event, severe gastrointestinal bleeding, cardiovascular (CV) or non-CV complications, or discontinuation of treatment because of an adverse event or events that were graded as serious or severe by original study authors.</p></fn><fn><p>**Defined as events resulting in death, hospital admission related to adverse events, cardiovascular events, stroke, and gastrointestinal bleeding.</p></fn><fn><p>***Undefined.</p></fn><fn><p>Abbreviations: ASA, Acetylsalicylic acid (aspirin); CPA, chemopreventive agent; DFMO, difluoromethylornithine; HD, high-dose; LD, low-dose; NSAID, non-steroidal anti-inflammatory drug; UDCA, ursodeoxycholic acid; VLD, very low-dose.</p></fn></table-wrap-foot></table-wrap></p><p>Other less commonly studied agents include antioxidants, berberine, and ursodeoxycholic acid (UDCA) (<xref rid="table2-10732748251344481" ref-type="table">Table 2</xref>). In NMAs, antioxidants are a category of interventions that include vitamin A, B6, B12, C, and E, &#x003b1;-tocopherol, beta-carotene, selenium and green tea extracts, either as single agent or as combinations. Four NMAs examined the effect of antioxidants, and no association was found for CRA or CRC.<sup><xref rid="bibr10-10732748251344481" ref-type="bibr">10</xref>,<xref rid="bibr13-10732748251344481" ref-type="bibr">13</xref>,<xref rid="bibr14-10732748251344481" ref-type="bibr">14</xref>,<xref rid="bibr18-10732748251344481" ref-type="bibr">18</xref></sup> No association was found for UDCA either.<sup><xref rid="bibr11-10732748251344481" ref-type="bibr">11</xref>,<xref rid="bibr14-10732748251344481" ref-type="bibr">14</xref></sup> Two NMAs examined berberine, a traditional Chinese medicine suggested to have anti-inflammatory and antitumor effects. One NMA found a non-significant effect of preventing any adenoma based on one RCT (RR: 0.72, 95% CI: 0.37-1.40).<sup>
<xref rid="bibr14-10732748251344481" ref-type="bibr">14</xref>
</sup> The other NMA found a significant effect based on three RCTs, two of which were published in Chinese language (RR: 0.79, 95% CI: 0.68-0.92).<sup>
<xref rid="bibr18-10732748251344481" ref-type="bibr">18</xref>
</sup></p></sec><sec sec-type="discussion" id="sec6-10732748251344481"><title>Discussion</title><p>Among all CPAs we have reviewed, Aspirin and non-aspirin NSAIDs such as celecoxib were the most well-studied. Aspirin demonstrated efficacy against the development of any CRA, but the effect against advanced CRA was not statistically significant. Non-aspirin NSAIDs have better efficacy against advanced CRA. However, the use of non-aspirin NSAIDs such as celecoxib was associated with significantly increased risk of serious AEs, particularly cardiovascular disease (CVD) events. Therefore, non-aspirin NSAIDs for CRC prevention are currently approved for use in people with familial adenomatous polyposis (FAP), and could be considered for people without underlying risk of CVD.<sup>
<xref rid="bibr25-10732748251344481" ref-type="bibr">25</xref>
</sup> On the other hand, low-dose aspirin is a more practical option for the prevention of recurrent CPA among both the high-risk and the general population, which only increases the risk of GI bleeding but not other serious AEs. In 2016, the US Preventive Services Task Force (USPSTF) endorsed low-dose aspirin for CRC prevention among adults aged 50-59 without an increased risk of bleeding.<sup>
<xref rid="bibr26-10732748251344481" ref-type="bibr">26</xref>
</sup> However, USPSTF withdrew this recommendation in 2022 because of updated RCT results indicating no reduced risk in CRC prevention.<sup>
<xref rid="bibr27-10732748251344481" ref-type="bibr">27</xref>
</sup> Although this decision was criticized by some researchers for biasedly selecting and interpreting evidence,<sup>
<xref rid="bibr28-10732748251344481" ref-type="bibr">28</xref>
</sup> it highlighted the urgency to better understand the ideal prevention windows, duration, and the characteristics of the patient subgroups who benefit more from aspirin use, and those individuals who are at greater risk of side effects.</p><p>It is important to note that all NMAs in this review used the adenoma detection rate (ADR) as the measure of efficacy, not the mean number of adenomas per person (APP), Because of the increasing quality of colonoscopy, the latter has been advocated as a more appropriate measure of efficacy in CPA trials.<sup><xref rid="bibr29-10732748251344481" ref-type="bibr">29</xref>,<xref rid="bibr30-10732748251344481" ref-type="bibr">30</xref></sup> An agent might reduce the APP but not the ADR. For example, in the seAFOod trial, aspirin did not show an effect on ADR. However, aspirin was associated with a 22% reduction in the APP.<sup>
<xref rid="bibr29-10732748251344481" ref-type="bibr">29</xref>
</sup></p><p>The preventive effects of CPAs often differ by patient subgroups, and chemoprevention might be more effective if targeted to the most appropriate population. For example, a body of literature has shown that aspirin works differentially among patient subgroups. In a RCT with low-dose aspirin among Japanese patients, a qualitative effect modification by smoking was observed: former and never smokers had marked reduction in CRA (OR: 0.37, 95% CI: 0.21-0.68), whereas current smokers had increased risk with aspirin use (OR: 3.45, 95% CI: 1.12-10.64).<sup>
<xref rid="bibr31-10732748251344481" ref-type="bibr">31</xref>
</sup> A cross-sectional study among the US population observed similar effects, that aspirin only protected against colorectal polyps among nonsmokers and this effect was lost among current smokers.<sup>
<xref rid="bibr32-10732748251344481" ref-type="bibr">32</xref>
</sup></p><p>CPAs may also have differential efficacy against different subtypes of CRC and CRA. CRC is a heterogeneous disease with various histological features, driver mutations, and molecular characterization.<sup>
<xref rid="bibr33-10732748251344481" ref-type="bibr">33</xref>
</sup> For example, in the seAFOod trial, aspirin was shown to reduce the number of adenomas in the right colon, particularly serrated adenomas, but was also associated with reduced risk of conventional colorectal adenomas. In contrast, eicosapentaenoic acid had an effect on left-sided and conventional colorectal adenomas but not on right-sided or serrated lesions.<sup>
<xref rid="bibr29-10732748251344481" ref-type="bibr">29</xref>
</sup> To date, most trials have not captured detailed information on the subtype of cancer or adenoma being prevented. Consequently, subtype and location-specific effects may have been missed and the benefits of these agents might have been underestimated.</p><p>Genetic variation is another important biomarker that moderates the effect of CPA. Several single nucleotide polymorphisms (SNPs) have been identified to modify the effect of aspirin on CRA or CRC prevention.<sup><xref rid="bibr34-10732748251344481" ref-type="bibr">34</xref>-<xref rid="bibr42-10732748251344481" ref-type="bibr">42</xref></sup> For example, a genotype analysis of the seAFOod Polyp Prevention Trial data showed that the chemoprevention effect by aspirin was modified by the SNPs in cyclooxygenase, lipoxygenase, and TP53 Genes.<sup>
<xref rid="bibr42-10732748251344481" ref-type="bibr">42</xref>
</sup> Participants with certain SNP genotypes of these genes benefited more from aspirin use than participants with other alleles. Likewise, although no NMAs found a protective effect of vitamin D supplementation, people with certain genetic traits might still benefit from it. One example is the genotype of vitamin D receptor. A RCT discovered that the effect of vitamin D supplementation is moderated by the rs7968585 allele.<sup>
<xref rid="bibr43-10732748251344481" ref-type="bibr">43</xref>
</sup> The AA genotype reduced risk by 64%, while AG or GG genotype increased risk by 41%. Recently, a secondary analysis of a vitamin D/calcium intervention RCT showed that individuals with certain vitamin D-binding protein isoforms may particularly benefit from vitamin D supplementation for CRA prevention.<sup>
<xref rid="bibr44-10732748251344481" ref-type="bibr">44</xref>
</sup> With the advancement of precision prevention, it is very likely that chemoprevention of CRA/CRC can be personalized.<sup><xref rid="bibr45-10732748251344481" ref-type="bibr">45</xref>,<xref rid="bibr46-10732748251344481" ref-type="bibr">46</xref></sup></p><p>Meanwhile, the search for repurposed CPAs is ongoing. It is challenging to find a good CPA. Due to the long duration of use, the CPA must be effective, have minimal side effects, and ideally, low cost. A few CPAs have received attention and are the subject of ongoing research, including metformin, berberine, and more recently, glucagon-like peptide-1 receptor agonists (GLP-1RA).</p><p>Metformin is a biguanide compound often used to treat type 2 diabetes. It possesses anticancer properties through a number of mechanisms including the activation of AMP-activated protein kinase, which inhibits the mTOR pathway that promotes cell proliferation.<sup>
<xref rid="bibr47-10732748251344481" ref-type="bibr">47</xref>
</sup> Observational studies show that metformin reduces the incidence of advanced CRA and CRC among diabetes patients.<sup>
<xref rid="bibr48-10732748251344481" ref-type="bibr">48</xref>
</sup> To date, there is only one RCT on metformin and chemoprevention of sporadic CRA that used endoscopy-confirmed CRA rates as outcome.<sup>
<xref rid="bibr49-10732748251344481" ref-type="bibr">49</xref>
</sup> Risk of CRA was significantly reduced among the metformin group. However, due to a short 1-year follow-up of this trial, the long-term effects of metformin on CRC prevention remains unclear. A recent target trial emulation using electronic health records suggests that metformin does not reduce the 6-year risk of CRC either among diabetes patients or patients regardless of diabetes status, which casts doubts on metformin as a CPA.<sup>
<xref rid="bibr50-10732748251344481" ref-type="bibr">50</xref>
</sup></p><p>Berberine is an alkaloid compound in several plants such as barberry and Chinese goldthread.<sup>
<xref rid="bibr51-10732748251344481" ref-type="bibr">51</xref>
</sup> It is commonly used in traditional Chinese medicine to treat infections and diarrhea, and as adjuvant treatment of type 2 diabetes, hyperlipidemia, and hypertension.<sup>
<xref rid="bibr52-10732748251344481" ref-type="bibr">52</xref>
</sup> Preclinical studies suggest that berberine has anti-inflammatory properties and potentially anti-tumor effects by activating AMP-activated protein kinase, one of the same targets as metformin.<sup>
<xref rid="bibr53-10732748251344481" ref-type="bibr">53</xref>
</sup> Berberine is well-tolerated in general, with mild AEs.<sup>
<xref rid="bibr54-10732748251344481" ref-type="bibr">54</xref>
</sup> However, we showed that its efficacy is inconsistent between the two NMAs that included this agent. Whether it is a good candidate for the prevention of CRC requires further investigation with RCTs of larger sample size and longer follow-up.</p><p>GLP-1RAs are a class of agents which mimic the endogenous hormone GLP-1. They are used to treat type 2 diabetes through the stimulation of insulin secretion.<sup>
<xref rid="bibr55-10732748251344481" ref-type="bibr">55</xref>
</sup> GLP-1RAs are also effective in weight loss by delaying gastric emptying, and by decreasing appetite and craving through a complex signaling to the brain.<sup>
<xref rid="bibr56-10732748251344481" ref-type="bibr">56</xref>
</sup> Because of the dual effects of GLP-1RAs, they have been proposed to act as a CPA for CRC. A recent retrospective cohort study showed that drug-na&#x000ef;ve diabetic patients treated with GLP-1RAs had 44% reduced risk of CRC (HR: 0.56, 95% CI: 0.44-0.72) compared to propensity-score matched patients treated with insulin.<sup>
<xref rid="bibr57-10732748251344481" ref-type="bibr">57</xref>
</sup> If this association can be ascertained in RCT among both diabetic patients and people with obesity, GLP-1RAs could be a highly effective CPAs in these individuals who are at elevated risk of CRC.</p><p>In this review, we focused on the chemoprevention of CRA and CRC. However, it is equally important to emphasize other prevention strategies. Considerable research has elucidated the impact of healthy lifestyle as an important prevention strategy, such as avoiding smoking, reducing alcohol consumption, having a healthy diet, proper weight management, and adequate physical activity.<sup><xref rid="bibr58-10732748251344481" ref-type="bibr">58</xref>-<xref rid="bibr60-10732748251344481" ref-type="bibr">60</xref></sup> Furthermore, organized early detection strategies are crucial for reducing CRC-related mortality. Both endoscopy-based tests and stool-based tests have demonstrated great benefits for both average and high-risk populations.<sup><xref rid="bibr3-10732748251344481" ref-type="bibr">3</xref>,<xref rid="bibr61-10732748251344481" ref-type="bibr">61</xref></sup> Blood tests, such as the cell-free DNA test, have emerged as an alternative screening approach with potentially better uptake and adherence.<sup>
<xref rid="bibr62-10732748251344481" ref-type="bibr">62</xref>
</sup> Finally, for high-risk populations with family history of CRA/CRC, genetic counseling should be considered to help guide prevention and early detection.<sup>
<xref rid="bibr63-10732748251344481" ref-type="bibr">63</xref>
</sup></p><sec id="sec7-10732748251344481"><title>Limitations</title><p>Although all NMAs were synthesized from RCT studies, there are still notable heterogeneities and potential for bias. Because of different research questions, each NMA had somewhat different inclusion and exclusion criteria. For example, some NMAs focused only on high-risk population while some also included average-risk population. Therefore, a different number of RCTs might be included even for the same intervention. Researchers might choose to administer different doses of a CPA (e.g., celecoxib, ASA) as different interventions, or choose to group as one intervention. RCTs also had varying durations of intervention, which might violate the transitivity assumption of NMA. However, most NMAs did not address this concern.</p><p>We did not pool the estimates from all NMAs in part because of the heterogeneity. Moreover, there was substantial overlapping in the included RCTs in each NMA. Pooling the estimates violates the independent observation requirement for meta-analysis. We only included NMAs of English language and we did not search grey literature for additional NMAs, although the likelihood of missing high-quality NMAs was very low. Lastly, we did not discuss all interventions from the NMAs. For example, we did not present the findings for balsalazide, metformin, eicosapentaenoic acid, resistant starch, and some combinations of CPA such as ASA and DFMO, ASA and EPA.</p></sec></sec><sec sec-type="conclusion" id="sec8-10732748251344481"><title>Conclusion</title><p>In summary, our review of NMAs on chemoprevention of CRA/CRC suggests that low-dose aspirin is currently the best option, considering the balance of efficacy and safety. Nevertheless, knowledge gaps remain on important aspects such as the characteristic of patients associated with better prevention efficacy, the personalized timing and dosing of intervention, new targets for prevention, and the coordination between chemoprevention and surveillance to achieve optimal real-world effectiveness. Future research is needed to better characterize the patient subgroups that benefit more from the existing CPAs, to develop a risk prediction tool that is tailored to personalize the dosing and surveillance interval, and to explore new CPAs with improved efficacy that can be used alone or in combination to provide broad and effective prevention of all subtypes of CRC.</p></sec><sec sec-type="supplementary-material" id="sec9-10732748251344481"><title>Supplemental Material</title><supplementary-material id="suppl1-10732748251344481" position="float" content-type="local-data"><caption><title>Supplemental Material - Review of Network Meta-Analyses on the Efficacy of Chemopreventive Agents on Colorectal Adenomas and Cancer</title></caption><media xlink:href="sj-pdf-1-ccx-10.1177_10732748251344481.pdf"/><p>Supplemental Material Review of Network Meta-Analyses on the Efficacy of Chemopreventive Agents on Colorectal Adenomas and Cancer by Yibing Ruan, Chantelle Carbonell, Karen Brown, Robert J. Hilsden, and Darren R. Brenner in Cancer Control</p></supplementary-material></sec></body><back><fn-group><fn fn-type="presented-by"><p><bold>Author Contributions:</bold> YR, CC, and DRB conceived and outlined the review. YR, CC and DRB collected data for use in the manuscript. YR and CC analyzed the collected articles and wrote the initial draft of the manuscript. All authors contributed to editing and revising the manuscript.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The authors received no financial support for the research, authorship, and/or publication of this article.</p></fn><fn fn-type="COI-statement"><p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></fn></fn-group><fn-group><fn fn-type="supplementary-material"><p><bold>Supplemental Material:</bold> Supplemental material for this article is available online.</p></fn></fn-group><sec sec-type="orcid" id="sec10-10732748251344481"><title>ORCID iD</title><p>Chantelle Carbonell <ext-link xlink:href="https://orcid.org/0009-0004-6384-3424" ext-link-type="uri">https://orcid.org/0009-0004-6384-3424</ext-link></p></sec><ref-list><title>References</title><ref id="bibr1-10732748251344481"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bray</surname><given-names>F</given-names></name>
<name><surname>Laversanne</surname><given-names>M</given-names></name>
<name><surname>Sung</surname><given-names>H</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J Clin</source>. <year>2024</year>;<volume>74</volume>:<fpage>229</fpage>-<lpage>263</lpage>. doi:<pub-id pub-id-type="doi">10.3322/caac.21834</pub-id><pub-id pub-id-type="pmid">38572751</pub-id>
</mixed-citation></ref><ref id="bibr2-10732748251344481"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brenner</surname><given-names>DR</given-names></name>
<name><surname>Gillis</surname><given-names>J</given-names></name>
<name><surname>Demers</surname><given-names>AA</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Projected estimates of cancer in Canada in 2024</article-title>. <source>Cmaj</source>. <year>2024</year>;<volume>196</volume>(<issue>18</issue>):<fpage>E615</fpage>-<lpage>e623</lpage>. doi:<pub-id pub-id-type="doi">10.1503/cmaj.240095</pub-id><pub-id pub-id-type="pmid">38740416</pub-id>
</mixed-citation></ref><ref id="bibr3-10732748251344481"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schreuders</surname><given-names>EH</given-names></name>
<name><surname>Ruco</surname><given-names>A</given-names></name>
<name><surname>Rabeneck</surname><given-names>L</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Colorectal cancer screening: a global overview of existing programmes</article-title>. <source>Gut</source>. <year>2015</year>;<volume>64</volume>(<issue>10</issue>):<fpage>1637</fpage>-<lpage>1649</lpage>. doi:<pub-id pub-id-type="doi">10.1136/gutjnl-2014-309086</pub-id><pub-id pub-id-type="pmid">26041752</pub-id>
</mixed-citation></ref><ref id="bibr4-10732748251344481"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Levin</surname><given-names>TR</given-names></name>
<name><surname>Corley</surname><given-names>DA</given-names></name>
<name><surname>Jensen</surname><given-names>CD</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Effects of organized colorectal cancer screening on cancer incidence and mortality in a large community-based population</article-title>. <source>Gastroenterology</source>. <year>2018</year>;<volume>155</volume>(<issue>5</issue>):<fpage>1383</fpage>-<lpage>1391.e5</lpage>. doi:<pub-id pub-id-type="doi">10.1053/j.gastro.2018.07.017</pub-id><pub-id pub-id-type="pmid">30031768</pub-id>
</mixed-citation></ref><ref id="bibr5-10732748251344481"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meyskens</surname><given-names>FL</given-names><suffix>Jr.</suffix></name>
<name><surname>Chemoprevention</surname><given-names>MLCE</given-names></name>
</person-group>. <article-title>Risk reduction, therapeutic prevention, or preventive therapy?</article-title>
<source>JNCI: J Natl Cancer Inst</source>. <year>2010</year>;<volume>102</volume>(<issue>24</issue>):<fpage>1815</fpage>-<lpage>1817</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jnci/djq466</pub-id><pub-id pub-id-type="pmid">21115881</pub-id>
</mixed-citation></ref><ref id="bibr6-10732748251344481"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chapelle</surname><given-names>N</given-names></name>
<name><surname>Martel</surname><given-names>M</given-names></name>
<name><surname>Toes-Zoutendijk</surname><given-names>E</given-names></name>
<name><surname>Barkun</surname><given-names>AN</given-names></name>
<name><surname>Bardou</surname><given-names>M</given-names></name>
</person-group>. <article-title>Recent advances in clinical practice: colorectal cancer chemoprevention in the average-risk population</article-title>. <source>Gut</source>. <year>2020</year>;<volume>69</volume>(<issue>12</issue>):<fpage>2244</fpage>-<lpage>2255</lpage>. doi:<pub-id pub-id-type="doi">10.1136/gutjnl-2020-320990</pub-id><pub-id pub-id-type="pmid">32989022</pub-id>
</mixed-citation></ref><ref id="bibr7-10732748251344481"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jansen</surname><given-names>JP</given-names></name>
<name><surname>Fleurence</surname><given-names>R</given-names></name>
<name><surname>Devine</surname><given-names>B</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1</article-title>. <source>Value Health</source>. <year>2011</year>;<volume>14</volume>(<issue>4</issue>):<fpage>417</fpage>-<lpage>428</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jval.2011.04.002</pub-id><pub-id pub-id-type="pmid">21669366</pub-id>
</mixed-citation></ref><ref id="bibr8-10732748251344481"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>T</given-names></name>
<name><surname>Puhan</surname><given-names>MA</given-names></name>
<name><surname>Vedula</surname><given-names>SS</given-names></name>
<name><surname>Singh</surname><given-names>S</given-names></name>
<name><surname>Dickersin</surname><given-names>K</given-names></name>
</person-group>. <article-title>Network meta-analysis-highly attractive but more methodological research is needed</article-title>. <source>BMC Med</source>. <year>2011</year>;<volume>9</volume>:<fpage>79</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1741-7015-9-79</pub-id><pub-id pub-id-type="pmid">21707969</pub-id>
</mixed-citation></ref><ref id="bibr9-10732748251344481"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fu</surname><given-names>Q</given-names></name>
<name><surname>Liao</surname><given-names>H</given-names></name>
<name><surname>Li</surname><given-names>Z</given-names></name>
<name><surname>Chen</surname><given-names>X</given-names></name>
<name><surname>Zhang</surname><given-names>X</given-names></name>
<name><surname>Di</surname><given-names>J</given-names></name>
</person-group>. <article-title>Preventive effects of 13 different drugs on colorectal cancer: a network meta-analysis</article-title>. <source>Arch Med Sci</source>. <year>2023</year>;<volume>19</volume>(<issue>5</issue>):<fpage>1428</fpage>-<lpage>1445</lpage>. doi:<pub-id pub-id-type="doi">10.5114/aoms/167480</pub-id><pub-id pub-id-type="pmid">37732038</pub-id>
</mixed-citation></ref><ref id="bibr10-10732748251344481"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Veettil</surname><given-names>SK</given-names></name>
<name><surname>Jinatongthai</surname><given-names>P</given-names></name>
<name><surname>Nathisuwan</surname><given-names>S</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Efficacy and safety of chemopreventive agents on colorectal cancer incidence and mortality: systematic review and network meta-analysis</article-title>. <source>Clin Epidemiol</source>. <year>2018</year>;<volume>10</volume>:<fpage>1433</fpage>-<lpage>1445</lpage>. doi:<pub-id pub-id-type="doi">10.2147/clep.S174120</pub-id><pub-id pub-id-type="pmid">30349391</pub-id>
</mixed-citation></ref><ref id="bibr11-10732748251344481"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>Y</given-names></name>
<name><surname>You</surname><given-names>W</given-names></name>
<name><surname>Cao</surname><given-names>Y</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Chemoprevention of colorectal cancer in general population and high-risk population: a systematic review and network meta-analysis</article-title>. <source>Chin Med J</source>. <year>2023</year>;<volume>136</volume>(<issue>7</issue>):<fpage>788</fpage>-<lpage>798</lpage>. doi:<pub-id pub-id-type="doi">10.1097/cm9.0000000000002514</pub-id><pub-id pub-id-type="pmid">37027286</pub-id>
</mixed-citation></ref><ref id="bibr12-10732748251344481"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shah</surname><given-names>D</given-names></name>
<name><surname>Di Re</surname><given-names>A</given-names></name>
<name><surname>Toh</surname><given-names>JWT</given-names></name>
</person-group>. <article-title>Aspirin chemoprevention in colorectal cancer: network meta-analysis of low, moderate, and high doses</article-title>. <source>Br J Surg</source>. <year>2023</year>;<volume>110</volume>(<issue>12</issue>):<fpage>1691</fpage>-<lpage>1702</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bjs/znad231</pub-id><pub-id pub-id-type="pmid">37499126</pub-id>
</mixed-citation></ref><ref id="bibr13-10732748251344481"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Veettil</surname><given-names>SK</given-names></name>
<name><surname>Teerawattanapong</surname><given-names>N</given-names></name>
<name><surname>Ching</surname><given-names>SM</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Effects of chemopreventive agents on the incidence of recurrent colorectal adenomas: a systematic review with network meta-analysis of randomized controlled trials</article-title>. <source>OncoTargets Ther</source>. <year>2017</year>;<volume>10</volume>:<fpage>2689</fpage>-<lpage>2700</lpage>. doi:<pub-id pub-id-type="doi">10.2147/ott.S127335</pub-id></mixed-citation></ref><ref id="bibr14-10732748251344481"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heer</surname><given-names>E</given-names></name>
<name><surname>Ruan</surname><given-names>Y</given-names></name>
<name><surname>Mah</surname><given-names>B</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>The efficacy of chemopreventive agents on the incidence of colorectal adenomas: a systematic review and network meta-analysis</article-title>. <source>Prev Med</source>. <year>2022</year>;<volume>162</volume>:<fpage>107169</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ypmed.2022.107169</pub-id><pub-id pub-id-type="pmid">35878711</pub-id>
</mixed-citation></ref><ref id="bibr15-10732748251344481"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hoang</surname><given-names>KD</given-names></name>
<name><surname>Chen</surname><given-names>JH</given-names></name>
<name><surname>Huang</surname><given-names>TW</given-names></name>
<name><surname>Kang</surname><given-names>YN</given-names></name>
<name><surname>Chen</surname><given-names>C</given-names></name>
</person-group>. <article-title>Oral aspirin for preventing colorectal adenoma recurrence: a systematic review and network meta-analysis of randomized controlled trials</article-title>. <source>PLoS One</source>. <year>2024</year>;<volume>19</volume>(<issue>3</issue>):<fpage>e0279784</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0279784</pub-id><pub-id pub-id-type="pmid">38483854</pub-id>
</mixed-citation></ref><ref id="bibr16-10732748251344481"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Veettil</surname><given-names>SK</given-names></name>
<name><surname>Kew</surname><given-names>ST</given-names></name>
<name><surname>Lim</surname><given-names>KG</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Very-low-dose aspirin and surveillance colonoscopy is cost-effective in secondary prevention of colorectal cancer in individuals with advanced adenomas: network meta-analysis and cost-effectiveness analysis</article-title>. <source>BMC Gastroenterol</source>. <year>2021</year>;<volume>21</volume>(<issue>1</issue>):<fpage>130</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12876-021-01715-7</pub-id><pub-id pub-id-type="pmid">33743605</pub-id>
</mixed-citation></ref><ref id="bibr17-10732748251344481"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dulai</surname><given-names>PS</given-names></name>
<name><surname>Singh</surname><given-names>S</given-names></name>
<name><surname>Marquez</surname><given-names>E</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis</article-title>. <source>Bmj</source>. <year>2016</year>;<volume>355</volume>:<fpage>i6188</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.i6188</pub-id><pub-id pub-id-type="pmid">27919915</pub-id>
</mixed-citation></ref><ref id="bibr18-10732748251344481"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tan</surname><given-names>S</given-names></name>
<name><surname>Ou</surname><given-names>Y</given-names></name>
<name><surname>Yang</surname><given-names>Y</given-names></name>
<name><surname>Huang</surname><given-names>S</given-names></name>
<name><surname>Chen</surname><given-names>S</given-names></name>
<name><surname>Gao</surname><given-names>Q</given-names></name>
</person-group>. <article-title>Preventive effects of chemical drugs on recurrence of colorectal adenomas: systematic review and Bayesian network meta-analysis</article-title>. <source>Eur J Gastroenterol Hepatol</source>. <year>2024</year>;<volume>36</volume>(<issue>1</issue>):<fpage>62</fpage>-<lpage>75</lpage>. doi:<pub-id pub-id-type="doi">10.1097/meg.0000000000002676</pub-id><pub-id pub-id-type="pmid">37942763</pub-id>
</mixed-citation></ref><ref id="bibr19-10732748251344481"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meyskens</surname><given-names>FL</given-names><suffix>Jr.</suffix></name>
<name><surname>McLaren</surname><given-names>CE</given-names></name>
<name><surname>Pelot</surname><given-names>D</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial</article-title>. <source>Cancer Prev Res (Phila)</source>. <year>2008</year>;<volume>1</volume>(<issue>1</issue>):<fpage>32</fpage>-<lpage>38</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1940-6207.Capr-08-0042</pub-id><pub-id pub-id-type="pmid">18841250</pub-id>
</mixed-citation></ref><ref id="bibr20-10732748251344481"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McGettigan</surname><given-names>P</given-names></name>
<name><surname>Henry</surname><given-names>D</given-names></name>
</person-group>. <article-title>Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2</article-title>. <source>JAMA</source>. <year>2006</year>;<volume>296</volume>(<issue>13</issue>):<fpage>1633</fpage>-<lpage>1644</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.296.13.jrv60011</pub-id><pub-id pub-id-type="pmid">16968831</pub-id>
</mixed-citation></ref><ref id="bibr21-10732748251344481"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>K</given-names></name>
<name><surname>Willett</surname><given-names>WC</given-names></name>
<name><surname>Fuchs</surname><given-names>CS</given-names></name>
<name><surname>Colditz</surname><given-names>GA</given-names></name>
<name><surname>Giovannucci</surname><given-names>EL</given-names></name>
</person-group>. <article-title>Calcium intake and risk of colon cancer in women and men</article-title>. <source>J Natl Cancer Inst</source>. <year>2002</year>;<volume>94</volume>(<issue>6</issue>):<fpage>437</fpage>-<lpage>446</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jnci/94.6.437</pub-id><pub-id pub-id-type="pmid">11904316</pub-id>
</mixed-citation></ref><ref id="bibr22-10732748251344481"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McCullough</surname><given-names>ML</given-names></name>
<name><surname>Zoltick</surname><given-names>ES</given-names></name>
<name><surname>Weinstein</surname><given-names>SJ</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Circulating vitamin D and colorectal cancer risk: an international pooling project of 17 cohorts</article-title>. <source>J Natl Cancer Inst</source>. <year>2019</year>;<volume>111</volume>(<issue>2</issue>):<fpage>158</fpage>-<lpage>169</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jnci/djy087</pub-id><pub-id pub-id-type="pmid">29912394</pub-id>
</mixed-citation></ref><ref id="bibr23-10732748251344481"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hubner</surname><given-names>RA</given-names></name>
<name><surname>Houlston</surname><given-names>RS</given-names></name>
</person-group>. <article-title>Folate and colorectal cancer prevention</article-title>. <source>Br J Cancer</source>. <year>2009</year>;<volume>100</volume>(<issue>2</issue>):<fpage>233</fpage>-<lpage>239</lpage>. doi:<pub-id pub-id-type="doi">10.1038/sj.bjc.6604823</pub-id><pub-id pub-id-type="pmid">19088716</pub-id>
</mixed-citation></ref><ref id="bibr24-10732748251344481"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zwart</surname><given-names>NRK</given-names></name>
<name><surname>Franken</surname><given-names>MD</given-names></name>
<name><surname>Tissing</surname><given-names>WJE</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Folate, folic acid, and chemotherapy-induced toxicities: a systematic literature review</article-title>. <source>Crit Rev Oncol Hematol</source>. <year>2023</year>;<volume>188</volume>:<fpage>104061</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.critrevonc.2023.104061</pub-id><pub-id pub-id-type="pmid">37353179</pub-id>
</mixed-citation></ref><ref id="bibr25-10732748251344481"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rostom</surname><given-names>A</given-names></name>
<name><surname>Dub&#x000e9;</surname><given-names>C</given-names></name>
<name><surname>Lewin</surname><given-names>G</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force</article-title>. <source>Ann Intern Med</source>. <year>2007</year>;<volume>146</volume>(<issue>5</issue>):<fpage>376</fpage>-<lpage>389</lpage>. doi:<pub-id pub-id-type="doi">10.7326/0003-4819-146-5-200703060-00010</pub-id><pub-id pub-id-type="pmid">17339623</pub-id>
</mixed-citation></ref><ref id="bibr26-10732748251344481"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bibbins-Domingo</surname><given-names>K</given-names></name>
</person-group>. <article-title>Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement</article-title>. <source>Ann Intern Med</source>. <year>2016</year>;<volume>164</volume>(<issue>12</issue>):<fpage>836</fpage>-<lpage>845</lpage>. doi:<pub-id pub-id-type="doi">10.7326/m16-0577</pub-id><pub-id pub-id-type="pmid">27064677</pub-id>
</mixed-citation></ref><ref id="bibr27-10732748251344481"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davidson</surname><given-names>KW</given-names></name>
<name><surname>Barry</surname><given-names>MJ</given-names></name>
<name><surname>Mangione</surname><given-names>CM</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Aspirin use to prevent cardiovascular disease: US preventive Services Task Force recommendation statement</article-title>. <source>JAMA</source>. <year>2022</year>;<volume>327</volume>(<issue>16</issue>):<fpage>1577</fpage>-<lpage>1584</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2022.4983</pub-id><pub-id pub-id-type="pmid">35471505</pub-id>
</mixed-citation></ref><ref id="bibr28-10732748251344481"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chan</surname><given-names>AT</given-names></name>
</person-group>. <article-title>Aspirin and the USPSTF-what about cancer?</article-title>
<source>JAMA Oncol</source>. <year>2022</year>;<volume>8</volume>(<issue>10</issue>):<fpage>1392</fpage>-<lpage>1394</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaoncol.2022.2967</pub-id><pub-id pub-id-type="pmid">35900749</pub-id>
</mixed-citation></ref><ref id="bibr29-10732748251344481"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hull</surname><given-names>MA</given-names></name>
<name><surname>Sprange</surname><given-names>K</given-names></name>
<name><surname>Hepburn</surname><given-names>T</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 &#x000d7; 2 factorial trial</article-title>. <source>Lancet</source>. <year>2018</year>;<volume>392</volume>(<issue>10164</issue>):<fpage>2583</fpage>-<lpage>2594</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0140-6736(18)31775-6</pub-id><pub-id pub-id-type="pmid">30466866</pub-id>
</mixed-citation></ref><ref id="bibr30-10732748251344481"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>TJ</given-names></name>
<name><surname>Rutter</surname><given-names>MD</given-names></name>
<name><surname>Blanks</surname><given-names>RG</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Colonoscopy quality measures: experience from the NHS bowel cancer screening programme</article-title>. <source>Gut</source>. <year>2012</year>;<volume>61</volume>(<issue>7</issue>):<fpage>1050</fpage>-<lpage>1057</lpage>. doi:<pub-id pub-id-type="doi">10.1136/gutjnl-2011-300651</pub-id><pub-id pub-id-type="pmid">21940723</pub-id>
</mixed-citation></ref><ref id="bibr31-10732748251344481"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ishikawa</surname><given-names>H</given-names></name>
<name><surname>Mutoh</surname><given-names>M</given-names></name>
<name><surname>Suzuki</surname><given-names>S</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial</article-title>. <source>Gut</source>. <year>2014</year>;<volume>63</volume>(<issue>11</issue>):<fpage>1755</fpage>-<lpage>1759</lpage>. doi:<pub-id pub-id-type="doi">10.1136/gutjnl-2013-305827</pub-id><pub-id pub-id-type="pmid">24488498</pub-id>
</mixed-citation></ref><ref id="bibr32-10732748251344481"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Drew</surname><given-names>DA</given-names></name>
<name><surname>Goh</surname><given-names>G</given-names></name>
<name><surname>Mo</surname><given-names>A</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Colorectal polyp prevention by daily aspirin use is abrogated among active smokers</article-title>. <source>Cancer Causes Control</source>. <year>2016</year>;<volume>27</volume>(<issue>1</issue>):<fpage>93</fpage>-<lpage>103</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10552-015-0686-1</pub-id><pub-id pub-id-type="pmid">26510933</pub-id>
</mixed-citation></ref><ref id="bibr33-10732748251344481"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fearon</surname><given-names>ER</given-names></name>
</person-group>. <article-title>Molecular genetics of colorectal cancer</article-title>. <source>Annu Rev Pathol</source>. <year>2011</year>;<volume>6</volume>(<issue>2011</issue>):<fpage>479</fpage>-<lpage>507</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev-pathol-011110-130235</pub-id><pub-id pub-id-type="pmid">21090969</pub-id>
</mixed-citation></ref><ref id="bibr34-10732748251344481"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chan</surname><given-names>AT</given-names></name>
<name><surname>Tranah</surname><given-names>GJ</given-names></name>
<name><surname>Giovannucci</surname><given-names>EL</given-names></name>
<name><surname>Hunter</surname><given-names>DJ</given-names></name>
<name><surname>Fuchs</surname><given-names>CS</given-names></name>
</person-group>. <article-title>Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma</article-title>. <source>J Natl Cancer Inst</source>. <year>2005</year>;<volume>97</volume>(<issue>6</issue>):<fpage>457</fpage>-<lpage>460</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jnci/dji066</pub-id><pub-id pub-id-type="pmid">15770010</pub-id>
</mixed-citation></ref><ref id="bibr35-10732748251344481"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nan</surname><given-names>H</given-names></name>
<name><surname>Hutter</surname><given-names>CM</given-names></name>
<name><surname>Lin</surname><given-names>Y</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants</article-title>. <source>JAMA</source>. <year>2015</year>;<volume>313</volume>(<issue>11</issue>):<fpage>1133</fpage>-<lpage>1142</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2015.1815</pub-id><pub-id pub-id-type="pmid">25781442</pub-id>
</mixed-citation></ref><ref id="bibr36-10732748251344481"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Seufert</surname><given-names>BL</given-names></name>
<name><surname>Poole</surname><given-names>EM</given-names></name>
<name><surname>Whitton</surname><given-names>J</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>I&#x003ba;BK&#x003b2; and NF&#x003ba;B1, NSAID use and risk of colorectal cancer in the Colon Cancer Family Registry</article-title>. <source>Carcinogenesis</source>. <year>2013</year>;<volume>34</volume>(<issue>1</issue>):<fpage>79</fpage>-<lpage>85</lpage>. doi:<pub-id pub-id-type="doi">10.1093/carcin/bgs296</pub-id><pub-id pub-id-type="pmid">23002237</pub-id>
</mixed-citation></ref><ref id="bibr37-10732748251344481"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ulrich</surname><given-names>CM</given-names></name>
<name><surname>Whitton</surname><given-names>J</given-names></name>
<name><surname>Yu</surname><given-names>JH</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>PTGS2 (COX-2) -765G &#x0003e; C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source>. <year>2005</year>;<volume>14</volume>(<issue>3</issue>):<fpage>616</fpage>-<lpage>619</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1055-9965.Epi-04-0510</pub-id><pub-id pub-id-type="pmid">15767339</pub-id>
</mixed-citation></ref><ref id="bibr38-10732748251344481"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scherer</surname><given-names>D</given-names></name>
<name><surname>Koepl</surname><given-names>LM</given-names></name>
<name><surname>Poole</surname><given-names>EM</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Genetic variation in UGT genes modify the associations of NSAIDs with risk of colorectal cancer: colon cancer family registry</article-title>. <source>Genes Chromosomes Cancer</source>. <year>2014</year>;<volume>53</volume>(<issue>7</issue>):<fpage>568</fpage>-<lpage>578</lpage>. doi:<pub-id pub-id-type="doi">10.1002/gcc.22167</pub-id><pub-id pub-id-type="pmid">24677636</pub-id>
</mixed-citation></ref><ref id="bibr39-10732748251344481"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nan</surname><given-names>H</given-names></name>
<name><surname>Morikawa</surname><given-names>T</given-names></name>
<name><surname>Suuriniemi</surname><given-names>M</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations</article-title>. <source>J Natl Cancer Inst</source>. <year>2013</year>;<volume>105</volume>(<issue>24</issue>):<fpage>1852</fpage>-<lpage>18561</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jnci/djt331</pub-id><pub-id pub-id-type="pmid">24317174</pub-id>
</mixed-citation></ref><ref id="bibr40-10732748251344481"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barry</surname><given-names>EL</given-names></name>
<name><surname>Mott</surname><given-names>LA</given-names></name>
<name><surname>Sandler</surname><given-names>RS</given-names></name>
<name><surname>Ahnen</surname><given-names>DJ</given-names></name>
<name><surname>Baron</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Variants downstream of the ornithine decarboxylase gene influence risk of colorectal adenoma and aspirin chemoprevention</article-title>. <source>Cancer Prev Res (Phila)</source>. <year>2011</year>;<volume>4</volume>(<issue>12</issue>):<fpage>2072</fpage>-<lpage>2082</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1940-6207.Capr-11-0300</pub-id><pub-id pub-id-type="pmid">21930798</pub-id>
</mixed-citation></ref><ref id="bibr41-10732748251344481"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bigler</surname><given-names>J</given-names></name>
<name><surname>Whitton</surname><given-names>J</given-names></name>
<name><surname>Lampe</surname><given-names>JW</given-names></name>
<name><surname>Fosdick</surname><given-names>L</given-names></name>
<name><surname>Bostick</surname><given-names>RM</given-names></name>
<name><surname>Potter</surname><given-names>JD</given-names></name>
</person-group>. <article-title>CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk</article-title>. <source>Cancer Res</source>. <year>2001</year>;<volume>61</volume>(<issue>9</issue>):<fpage>3566</fpage>-<lpage>3569</lpage>.<pub-id pub-id-type="pmid">11325819</pub-id>
</mixed-citation></ref><ref id="bibr42-10732748251344481"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davies</surname><given-names>JR</given-names></name>
<name><surname>Mell</surname><given-names>T</given-names></name>
<name><surname>Fuller</surname><given-names>H</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Polymorphisms in cyclooxygenase, lipoxygenase, and TP53 genes predict colorectal polyp risk reduction by aspirin in the seAFOod polyp prevention trial</article-title>. <source>Cancer Prev Res</source>. <year>2023</year>;<volume>16</volume>(<issue>11</issue>):<fpage>621</fpage>-<lpage>629</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-23-0111</pub-id></mixed-citation></ref><ref id="bibr43-10732748251344481"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barry</surname><given-names>EL</given-names></name>
<name><surname>Peacock</surname><given-names>JL</given-names></name>
<name><surname>Rees</surname><given-names>JR</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Vitamin D receptor genotype, vitamin D3 supplementation, and risk of colorectal adenomas: a randomized clinical trial</article-title>. <source>JAMA Oncol</source>. <year>2017</year>;<volume>3</volume>(<issue>5</issue>):<fpage>628</fpage>-<lpage>635</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaoncol.2016.5917</pub-id><pub-id pub-id-type="pmid">27978548</pub-id>
</mixed-citation></ref><ref id="bibr44-10732748251344481"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gibbs</surname><given-names>DC</given-names></name>
<name><surname>Barry</surname><given-names>EL</given-names></name>
<name><surname>Fedirko</surname><given-names>V</given-names></name>
<name><surname>Baron</surname><given-names>JA</given-names></name>
<name><surname>Bostick</surname><given-names>RM</given-names></name>
</person-group>. <article-title>Impact of common vitamin D&#x02013;binding protein isoforms on supplemental vitamin D3 and/or calcium effects on colorectal adenoma recurrence risk: a secondary analysis of a randomized clinical trial</article-title>. <source>JAMA Oncol</source>. <year>2023</year>;<volume>9</volume>(<issue>4</issue>):<fpage>546</fpage>-<lpage>551</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaoncol.2022.6924</pub-id><pub-id pub-id-type="pmid">36701139</pub-id>
</mixed-citation></ref><ref id="bibr45-10732748251344481"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pearson</surname><given-names>TA</given-names></name>
<name><surname>Vitalis</surname><given-names>D</given-names></name>
<name><surname>Pratt</surname><given-names>C</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>The science of precision prevention: research opportunities and clinical applications to reduce cardiovascular health disparities</article-title>. <source>JACC Adv</source>. <year>2024</year>;<volume>3</volume>(<issue>1</issue>):<fpage>100759</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jacadv.2023.100759</pub-id><pub-id pub-id-type="pmid">38375059</pub-id>
</mixed-citation></ref><ref id="bibr46-10732748251344481"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vineis</surname><given-names>P</given-names></name>
<name><surname>Wild</surname><given-names>CP</given-names></name>
</person-group>. <article-title>The science of precision prevention of cancer</article-title>. <source>Lancet Oncol</source>. <year>2017</year>;<volume>18</volume>(<issue>8</issue>):<fpage>997</fpage>-<lpage>998</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1470-2045(17)30331-5</pub-id><pub-id pub-id-type="pmid">28759370</pub-id>
</mixed-citation></ref><ref id="bibr47-10732748251344481"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hosono</surname><given-names>K</given-names></name>
<name><surname>Endo</surname><given-names>H</given-names></name>
<name><surname>Takahashi</surname><given-names>H</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase</article-title>. <source>Mol Carcinog</source>. <year>2010</year>;<volume>49</volume>(<issue>7</issue>):<fpage>662</fpage>-<lpage>671</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mc.20637</pub-id><pub-id pub-id-type="pmid">20564343</pub-id>
</mixed-citation></ref><ref id="bibr48-10732748251344481"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ng</surname><given-names>C-AW</given-names></name>
<name><surname>Jiang</surname><given-names>AA</given-names></name>
<name><surname>Toh</surname><given-names>EMS</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression</article-title>. <source>Int J Colorectal Dis</source>. <year>2020</year>;<volume>35</volume>(<issue>8</issue>):<fpage>1501</fpage>-<lpage>1512</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00384-020-03676-x</pub-id><pub-id pub-id-type="pmid">32592092</pub-id>
</mixed-citation></ref><ref id="bibr49-10732748251344481"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Higurashi</surname><given-names>T</given-names></name>
<name><surname>Hosono</surname><given-names>K</given-names></name>
<name><surname>Takahashi</surname><given-names>H</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial</article-title>. <source>Lancet Oncol</source>. <year>2016</year>;<volume>17</volume>(<issue>4</issue>):<fpage>475</fpage>-<lpage>483</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s1470-2045(15)00565-3</pub-id><pub-id pub-id-type="pmid">26947328</pub-id>
</mixed-citation></ref><ref id="bibr50-10732748251344481"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dickerman</surname><given-names>BA</given-names></name>
<name><surname>Garc&#x000ed;a-Alb&#x000e9;niz</surname><given-names>X</given-names></name>
<name><surname>Logan</surname><given-names>RW</given-names></name>
<name><surname>Denaxas</surname><given-names>S</given-names></name>
<name><surname>Hern&#x000e1;n</surname><given-names>MA</given-names></name>
</person-group>. <article-title>Evaluating metformin strategies for cancer prevention: a target trial emulation using electronic health records</article-title>. <source>Epidemiology</source>. <year>2023</year>;<volume>34</volume>(<issue>5</issue>):<fpage>690</fpage>-<lpage>699</lpage>.<pub-id pub-id-type="pmid">37227368</pub-id>
</mixed-citation></ref><ref id="bibr51-10732748251344481"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Neag</surname><given-names>MA</given-names></name>
<name><surname>Mocan</surname><given-names>A</given-names></name>
<name><surname>Echeverr&#x000ed;a</surname><given-names>J</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Berberine: botanical occurrence, traditional uses, extraction methods, and relevance in cardiovascular, metabolic, hepatic, and renal disorders</article-title>. <source>Front Pharmacol</source>. <year>2018</year>;<volume>9</volume>:<fpage>557</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fphar.2018.00557</pub-id><pub-id pub-id-type="pmid">30186157</pub-id>
</mixed-citation></ref><ref id="bibr52-10732748251344481"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lan</surname><given-names>J</given-names></name>
<name><surname>Zhao</surname><given-names>Y</given-names></name>
<name><surname>Dong</surname><given-names>F</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension</article-title>. <source>J Ethnopharmacol</source>. <year>2015</year>;<volume>161</volume>:<fpage>69</fpage>-<lpage>81</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jep.2014.09.049</pub-id><pub-id pub-id-type="pmid">25498346</pub-id>
</mixed-citation></ref><ref id="bibr53-10732748251344481"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pirillo</surname><given-names>A</given-names></name>
<name><surname>Catapano</surname><given-names>AL</given-names></name>
</person-group>. <article-title>Berberine, a plant alkaloid with lipid- and glucose-lowering properties: from in vitro evidence to clinical studies</article-title>. <source>Atherosclerosis</source>. <year>2015</year>;<volume>243</volume>(<issue>2</issue>):<fpage>449</fpage>-<lpage>461</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2015.09.032</pub-id><pub-id pub-id-type="pmid">26520899</pub-id>
</mixed-citation></ref><ref id="bibr54-10732748251344481"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>C</given-names></name>
<name><surname>Tao</surname><given-names>C</given-names></name>
<name><surname>Liu</surname><given-names>Z</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>A randomized clinical trial of berberine hydrochloride in patients with diarrhea-predominant irritable bowel syndrome</article-title>. <source>Phytother Res</source>. <year>2015</year>;<volume>29</volume>(<issue>11</issue>):<fpage>1822</fpage>-<lpage>1827</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ptr.5475</pub-id><pub-id pub-id-type="pmid">26400188</pub-id>
</mixed-citation></ref><ref id="bibr55-10732748251344481"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baggio</surname><given-names>LL</given-names></name>
<name><surname>Drucker</surname><given-names>DJ</given-names></name>
</person-group>. <article-title>Biology of incretins: GLP-1 and GIP</article-title>. <source>Gastroenterology</source>. <year>2007</year>;<volume>132</volume>(<issue>6</issue>):<fpage>2131</fpage>-<lpage>2157</lpage>. doi:<pub-id pub-id-type="doi">10.1053/j.gastro.2007.03.054</pub-id><pub-id pub-id-type="pmid">17498508</pub-id>
</mixed-citation></ref><ref id="bibr56-10732748251344481"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baggio</surname><given-names>LL</given-names></name>
<name><surname>Drucker</surname><given-names>DJ</given-names></name>
</person-group>. <article-title>Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight</article-title>. <source>J Clin Investig</source>. <year>2014</year>;<volume>124</volume>(<issue>10</issue>):<fpage>4223</fpage>-<lpage>4226</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI78371</pub-id><pub-id pub-id-type="pmid">25202976</pub-id>
</mixed-citation></ref><ref id="bibr57-10732748251344481"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>L</given-names></name>
<name><surname>Wang</surname><given-names>W</given-names></name>
<name><surname>Kaelber</surname><given-names>DC</given-names></name>
<name><surname>Xu</surname><given-names>R</given-names></name>
<name><surname>Berger</surname><given-names>NA</given-names></name>
</person-group>. <article-title>GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight/obesity</article-title>. <source>JAMA Oncol</source>. <year>2023</year>;<volume>10</volume>:<fpage>256</fpage>-<lpage>258</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaoncol.2023.5573</pub-id></mixed-citation></ref><ref id="bibr58-10732748251344481"><label>58</label><mixed-citation publication-type="other"><person-group person-group-type="author">
<collab>Canadian Cancer Society</collab>
</person-group>. <article-title>Reducing your risk of colorectal cancer</article-title>. <ext-link xlink:href="https://cancer.ca/en/cancer-information/cancer-types/colorectal/risks/reducing-your-risk" ext-link-type="uri">https://cancer.ca/en/cancer-information/cancer-types/colorectal/risks/reducing-your-risk</ext-link>. <comment>Accessed 17 April 2025.</comment></mixed-citation></ref><ref id="bibr59-10732748251344481"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boyle</surname><given-names>T</given-names></name>
<name><surname>Keegel</surname><given-names>T</given-names></name>
<name><surname>Bull</surname><given-names>F</given-names></name>
<name><surname>Heyworth</surname><given-names>J</given-names></name>
<name><surname>Fritschi</surname><given-names>L</given-names></name>
</person-group>. <article-title>Physical activity and risks of proximal and distal colon cancers: a systematic review and meta-analysis</article-title>. <source>J Natl Cancer Inst</source>. <year>2012</year>;<volume>104</volume>(<issue>20</issue>):<fpage>1548</fpage>-<lpage>1561</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jnci/djs354</pub-id><pub-id pub-id-type="pmid">22914790</pub-id>
</mixed-citation></ref><ref id="bibr60-10732748251344481"><label>60</label><mixed-citation publication-type="book"><person-group person-group-type="author">
<collab>World Cancer Research Fund/American Institute for Cancer Research</collab>
</person-group>. <source>Diet, Nutrition, Physical Activity and Cancer: A Global Perspective. Continuous Update Project Expert Report</source>. <year>2018</year>. <comment>dietandcancerreport.org</comment>.</mixed-citation></ref><ref id="bibr61-10732748251344481"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Force</surname><given-names>UPST</given-names></name>
<name><surname>Davidson</surname><given-names>KW</given-names></name>
<name><surname>Barry</surname><given-names>MJ</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Screening for colorectal cancer: US preventive Services Task Force recommendation statement</article-title>. <source>JAMA</source>. <year>2021</year>;<volume>325</volume>(<issue>19</issue>):<fpage>1965</fpage>-<lpage>1977</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2021.6238</pub-id><pub-id pub-id-type="pmid">34003218</pub-id>
</mixed-citation></ref><ref id="bibr62-10732748251344481"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chung</surname><given-names>DC</given-names></name>
<name><surname>Gray Darrell</surname><given-names>M</given-names></name>
<name><surname>Singh</surname><given-names>H</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>A cell-free DNA blood-based test for colorectal cancer screening</article-title>. <source>N Engl J Med</source>. <year>2024</year>;<volume>390</volume>(<issue>11</issue>):<fpage>973</fpage>-<lpage>983</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2304714</pub-id><pub-id pub-id-type="pmid">38477985</pub-id>
</mixed-citation></ref><ref id="bibr63-10732748251344481"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heald</surname><given-names>B</given-names></name>
<name><surname>Hampel</surname><given-names>H</given-names></name>
<name><surname>Church</surname><given-names>J</given-names></name>
</person-group>, <etal>et al.</etal>
<article-title>Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Position statement on multigene panel testing for patients with colorectal cancer and/or polyposis</article-title>. <source>Fam Cancer</source>. <year>2020</year>;<volume>19</volume>(<issue>3</issue>):<fpage>223</fpage>-<lpage>239</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10689-020-00170-9</pub-id><pub-id pub-id-type="pmid">32172433</pub-id>
</mixed-citation></ref></ref-list><app-group><app id="app1-10732748251344481"><label>Appendix</label><sec><title>Abbreviations</title><def-list><def-item><term id="G1-10732748251344481">ADR</term><def><p>adenoma detection rate</p></def></def-item><def-item><term id="G2-10732748251344481">AE</term><def><p>Adverse event</p></def></def-item><def-item><term id="G3-10732748251344481">APP</term><def><p>adenomas per person</p></def></def-item><def-item><term id="G4-10732748251344481">ASA</term><def><p>Acetylsalicylic acid (aspirin)</p></def></def-item><def-item><term id="G5-10732748251344481">CI</term><def><p>confidence interval</p></def></def-item><def-item><term id="G6-10732748251344481">Cox-2</term><def><p>cyclooxygenase-2</p></def></def-item><def-item><term id="G7-10732748251344481">CPA</term><def><p>chemopreventive agent</p></def></def-item><def-item><term id="G8-10732748251344481">CRC</term><def><p>colorectal cancer</p></def></def-item><def-item><term id="G9-10732748251344481">CRA</term><def><p>colorectal adenoma</p></def></def-item><def-item><term id="G10-10732748251344481">CVD</term><def><p>cardiovascular disease</p></def></def-item><def-item><term id="G11-10732748251344481">FAP</term><def><p>familial adenomatous polyposis</p></def></def-item><def-item><term id="G12-10732748251344481">GI</term><def><p>gastrointestinal</p></def></def-item><def-item><term id="G13-10732748251344481">GLP-1RA</term><def><p>glucagon-like peptide-1 receptor agonists</p></def></def-item><def-item><term id="G14-10732748251344481">NMA</term><def><p>network meta-analysis</p></def></def-item><def-item><term id="G15-10732748251344481">OR</term><def><p>odds ratio</p></def></def-item><def-item><term id="G16-10732748251344481">RCT</term><def><p>randomized controlled trials</p></def></def-item><def-item><term id="G17-10732748251344481">RR</term><def><p>risk ratio</p></def></def-item><def-item><term id="G18-10732748251344481">NSAID</term><def><p>non-steroidal anti-inflammatory drug</p></def></def-item><def-item><term id="G19-10732748251344481">UDCA</term><def><p>ursodeoxycholic acid</p></def></def-item></def-list></sec></app></app-group></back></article>